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ABSTRACT 
 
             Overnutrition causes many metabolic diseases including type 2 diabetes. 
PFKFB3/iPFK2 is a master regulator of adipocyte and intestinal nutrient metabolism. 
Using PFKFB3/iPFK2+/– mice and adipocyte-specific PFKFB3 over-expression mice, 
the present study investigated the role of PFKFB3/iPFK2 in regulating diet-induced 
adiposity, inflammation in adipose tissue and intestine, and systemic insulin resistance. 
  On a high-fat diet (HFD), PFKFB3+/– mice gained much less body weight than 
did wild-type littermates. However, HFD-induced systemic insulin resistance in 
PFKFB3+/– mice was more severe than in wild-type littermates. In contrast, adipocyte-
specific PFKFB3 over-expression increased adiposity but suppressed overnutrition 
induced adipose tissue inflammatory response and improved insulin sensitivity. In 
addition to adipose tissue, PFKFB3/iPFK2 also played a role in intestine events. 
Compared to wild-type littermates, PFKFB3+/– mice displayed a significant increase in 
the expression of intestinal inflammatory markers on a HFD.  
In conclusion, PFKFB3 protects against overnutrition-induced adipose tissue and 
intestine inflammatory response and systemic insulin resistance in an adiposity-
independent manner. Selective PFKFB3 activation may be viable for treating and/or 
preventing insulin resistance and type 2 diabetes. 
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NOMENCLATURE 
6PFK1                        6-phosphofructo-1-kinase 
AMPK                        5’ Adenosine Monophosphate-activated Protein Kinase 
AP-1                            Activator Protein 1 
CPT1                           Carnitine Palmitoyltransferase I 
CRP                             C-reactive Protein 
Ctrl                               Control 
F2,6BP                         Fructose 2,6-bisphosphate 
FABPs                         Fatty Acid Binding Proteins 
FFAs                            Free Fatty Acids 
FAS                             Fatty Acyl-CoA Synthase  
GLUT4                        Glucose Transporter 4 
GTT                             Glucose Tolerance Test 
HFD                             High Fat Diet 
IKK                              IκB Kinase 
IL-1ra                           Interleulik-1 receptor antagonist 
IL-6                              Interleukin-6 
IL-10                            Interleukin-10 
INS                               Insulin 
iPFK2                           Inducible 6-phosphofructo-2-kinase 
IR                                  Insulin Resistance 
ITT                                Insulin Tolerance Test 
 v 
 
JNK                               c-Jun N-terminal kinase 
LXR                              Liver X Receptor 
MCP-1                          Monocyte Chemotactic Protein-1 
Nac                               N-acetyl-L-cysteine 
NFκB                            Nuclear Factor kB 
PGC1                            PPAR Gamma Co-activator 1 
PI3K                             Phosphatidylinositol-3 Kinase 
PPAR                            Peroxisome Proliferator-activated Receptor 
PPARα                          Peroxisome Proliferator-activated Receptor Alpha 
PPARγ                          Peroxisome Proliferator-activated Receptor Gamma 
PPREs                          PPARγ Response Elements  
ROS   Reactive Oxygen Species 
RT-PCR   Reverse Transcription Polymerase Chain Reaction 
RXR                              Retinoid X Receptor  
T2DM   Type 2 Diabetes Mellitus 
TG   Triglycerides 
TNF α   Tumor Necrosis Factor α 
TZDs                             Thiazolidinediones 
WAT                             White Adipose Tissue 
 vi 
 
TABLE OF CONTENTS 
 
              Page 
ABSTRACT ..............................................................................................................  ii  
ACKNOWLEDGEMENTS ......................................................................................  i?? 
NOMENCLATURE ..................................................................................................  ?? 
TABLE OF CONTENTS ..........................................................................................  vi 
LIST OF FIGURES ...................................................................................................  ???? 
LIST OF TABLES ....................................................................................................  xi 
CHAPTER I  INTRODUCTION ..........................................................................  1 
CHAPTER II  LITERATURE REVIEW ...............................................................  3 
 Metabolic syndrome, obesity, and type 2 diabetes .............................................?  3 
      Inflammation: a causal factor of obesity-related  
      insulin resistance and diabetes??????????????????????????????????????????????????????????????????????????????      ? 
      Adipose tissue function and inflammation???????????????????????????????????????????????????????????     1?
     
      Intestinal function and inflammation???????????????????????????????????????????????????????????????????     1? 
      Peroxisome proliferator-activated receptor γ (PPARγ)????????????????????????????????????????    15 
      PFKFB3/iPFK2????????????????????????????????????????????????????????????????????????????????????????????????????   18 
      Summary??????????????????????????????????????????????????????????????????????????????????????????????????????????????    20     
CHAPTER III THE ROLE OF PFKFB3/iPFK2 IN MOUSE ADIPOSE TISSUE 
METABOLISM, INFLAMMATORY RESPONSE, AND SYSTEMIC INSULIN 
RESISTANCE …… ................................................................................................      22
 
      Introduction  ........................................................................................................      22
 Materials and methods ........................................................................................  24 
 Results of animal studies .....................................................................................  30 
 Results of cell culture studies ..............................................................................  52 
      Discussion ........... .............................................................................................      62 
 
 
 
 
 vii 
 
Page 
CHAPTER IV THE ROLE OF PFKFB3/iPFK2 IN THE ANTI-DIABETIC 
 EFFECT OF PPARγ ACTIVATION .......................................................................      65 
      Introduction  ........................................................................................................      65 
 Materials and methods ........................................................................................  67 
 Results ???????????????..................................................................................................      72 
      Discussion????????....................................................................................................      89
CHAPTER V THE ROLE OF PFKFB3/iPFK2 IN OVERNUTRITION- 
RELATED INTESTINE INFLAMMATION ...........................................................      92 
      Introduction  ........................................................................................................      92 
 Materials and methods ........................................................................................  95 
 Results????????????......................................................................................................     98 
      Discussion?????.......................................................................................................    106 
 
CHAPTER VI SUMMARY AND CONCLUSIONS .............................................     108 
      Summary???????.......................................................................................................    108 
      Conclusions??????....................................................................................................    117 
REFERENCES ..........................................................................................................    120 
 
 
 viii 
 
LIST OF FIGURES 
 
                                                                                                                                       Page 
 
Figure 1 Leading Causes of Death Altered in US ...................................................  4 
 
Figure 2  Characteristic Features of Metabolic Syndrome .......................................  6 
 
Figure 3 Pathogenesis of the Metabolic Syndrome .................................................  7 
 
Figure 4 Molecular Pathways Linked between  
  Inflammatory Response and Insulin Action ..............................................  10 
 
Figure 5 Obese Adipose Tissue Inflammation and Macrophage Infiltration ..........  13 
Figure 6  Mechanisms for Anti-diabetic Effects of PPARγ Activation ....................      17 
 
Figure 7  PFKFB3/iPFK2 Coordinates Adipocyte Glucose and Lipid Metabolism  19 
 
Figure 8 The Distribution of PFKFB3/iPFK2 .........................................................  31 
 
Figure 9  The Confirmation of PFKFB3+/– Mice ......................................................  32 
 
Figure 10  Changes of PFKFB3 mRNA and iPFK2 Amount and  
                 Activity in PFKFB3+/– Mice .....................................................................  34 
 
Figure 11 Disruption of PFKFB3/iPFK2 Blunts HFD-induced Weight Gain ..........  35 
 
Figure 12 Disruption of PFKFB3/iPFK2 Blunts HFD-induced Adiposity ...............  36 
 
Figure 13 Disruption of PFKFB3/iPFK2 Alters Adipose Tissue Lipolysis ..............  37 
 
Figure 14 Disruption of PFKFB3/iPFK2 Alters Adipokine Expression ...................  39 
 
Figure 15  The Effects of PFKFB3/iPFK2 Disruption on  
                 Macrophage Infiltration ............................................................................  40 
 
Figure 16 Disruption of PFKFB3/iPFK2 Exacerbates HFD-induced Adipose Tissue 
                 Inflammatory Response ............................................................................  42 
 
Figure 17 Disruption of PFKFB3/iPFK2 Increases Adipose Expression of  
                Genes involved in Fatty Acid Oxidation ...................................................  44 
 
 ix 
 
 
Figure 18 Disruption of PFKFB3/iPFK2 Alters Adipose Tissue  
                Insulin Signaling     ...................................................................................  45 
 
Figure 19 Disruption of PFKFB3/iPFK2 Exacerbates HFD-induced   
                Systemic Insulin Resistance     ..................................................................  46 
 
Figure 20 The Generation of PFKFB3/iPFK2-adipocyte-specific  
                 Overexpression Mice   ..............................................................................  48 
 
Figure 21 Adipocyte-specific PFKFB3/iPFK2 Overexpression  
                 Increases Body Weight and Adiposity   ...................................................  50 
 
Figure 22 Adipocyte-specific PFKFB3/iPFK2 Overexpression  
                 Protects Against Overnutrition-induced Insulin Resistance and  
                 Glucose Intolerance ..................................................................................  51 
 
Figure 23 Adipocyte-specific PFKFB3/iPFK2 Overexpression  
                Suppresses Overnutrition-induced Adipose Tissue Inflammatory  
                Response and Increases Insulin Sensitivity ...............................................  53 
 
Figure 24 Knockdown of PFKFB3/iPFK2 Decreases Adipocyte Lipid  
                Accumulation by Suppressing the Conversion of Glucose into Lipid ......  54 
 
Figure 25 PFKFB3/iPFK2 Knockdown Exacerbates Adipocyte 
                Inflammatory Response .............................................................................  56 
 
Figure 26 ROS Generated by Excessive Fatty Acid Oxidation 
                Triggers Adipocyte Inflammatory Response   ..........................................  58 
 
Figure 27 PFKFB3/iPFK2 Knockdown Induces Adipocyte Dysfunction   ..............  59 
 
Figure 28 PFKFB3/iPFK2 Overexpression Increases Fat Deposition ......................  60 
 
Figure 29 PFKFB3/iPFK2 Overexpression Decreases Adipocyte  
                 Inflammatory Response and Improves Insulin Signaling  
                 While Increasing Fat Deposition ..............................................................  61
 
Figure 30 Disruption of PFKFB3/iPFK2 Blunts the Anti-diabetic  
                Effect of PPARγ Activation ......................................................................  73 
 
Figure 31 Disruption of PFKFB3/iPFK2 Impairs the Response of Adipose 
                 Tissue PFKFB3/iPFK2 to PPARγ Activation ..........................................  75 
 
 x 
 
Figure 32 Disruption of PFKFB3/iPFK2 does not Impair the Response of  
                 Other PPARγ Target Genes to PPARγ Activation ...................................  77 
 
Figure 33 Disruption of PFKFB3/iPFK2 Lessens the Effect of  
                 PPARγ Activation on Increasing Adipose Tissue Fat Storage ................  78 
 
Figure 34 Disruption of PFKFB3/iPFK2 Blunts the Effects of PPARγ Activation  
                 on Suppression of HFD-induced Adipose Tissue Inflammatory  
                 Response and on Reversal of Adipose Tissue Dysfunction .....................  81 
 
Figure 35 Knockdown of PFKFB3/iPFK2 Lessens the Effect of PPARγ  
                Activation on Stimulating Adipocyte Lipid Accumulation ......................  83 
 
Figure 36 Knockdown of PFKFB3/iPFK2 Diminishes the Effects of PPARγ  
                Activation on Suppression of Adipocyte Inflammatory Responses ..........  84 
 
Figure 37 Knockdown of PFKFB3/iPFK2 Diminishes the Effects of PPARγ  
                Activation on Improvement of Adipocyte Function .................................  86 
 
Figure 38 Inhibition of Fatty Acid Oxidation Restores the Effects of PPARγ  
                Activation on both Suppression of Adipocyte Inflammatory Response and  
                Stimulation of Adipocyte Insulin Signaling ..............................................  88 
 
Figure 39 PFKFB3/iPFK2 Expression in Key Metabolic Tissues ............................  98 
 
Figure 40 Dietary Effects on the Expression of PFKFB3/iPFK2 in the Intestine .....  100 
 
Figure 41 Dietary Effects of HFD Feeding on Intestine Inflammatory Responses...  100 
 
Figure 42 The Effects of PFKFB3/iPFK2 Disruption on Dietary Response of  
                Intestine iPFK2 ..........................................................................................  101 
 
Figure 43 Involvement of PFKFB3/iPFK2 in the Effect of PPARγ Activation on  
                Diet-induced Intestine Inflammatory Response ........................................  104 
 
Figure 44 Altered Composition of the Intestinale Microbiota ..................................  105 
 
Figure 45 PFKFB3/iPFK2 Regulation of Systemic Insulin Sensitivity ....................  106 
 
Figure 46 Scheme for the Role of PFKFB3/iPFK2 in Regulating Metabolic and   
                Inflammatory Responses ...........................................................................  119 
 
 
 xi 
 
LIST OF TABLES 
 
                                                                                                                                  Page 
Table 1 Selected Adipose Genes That Are Altered by  
  Disruption of PFKFB3/iPFK2 ...................................................................  43 
Table 2 Changes in the Levels of Plasma Metabolites and Insulin ........................  47
 1 
 
 
 
CHAPTER I 
 
INTRODUCTION  
 
 It has been shown that adipose tissue plays an essential role in the regulation of 
systemic metabolic homeostasis. In adipocytes, PFKFB3 is the gene that encodes for the 
inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK2), which is a 
regulatory enzyme of glycolysis. In mouse models of diabetes and/or insulin resistance, 
the expression of adipose PFKFB3 is decreased, which is accompanied by 
hyperglycemia and insulin resistance.  Upon the treatment of anti-diabetic agents, i.e., 
thiazolidinediones (TZDs), the expression of PFKFB3 in adipocytes is induced, which 
may be required, at least in part, for the effect of TZDs on restoring euglycemia and 
insulin sensitivity in mice.  These data pointed to a pivotal role of adipose PFKFB3 in 
the regulation of systemic glucose homeostasis and insulin sensitivity. Recently, it was 
found that PFKFB3/iPFK2 is highly expressed in the intestine. Additionally, much 
evidence demonstrates that the intestine is involved in the regulation of glucose 
hemostasis and inflammatory responses. However, the mechanisms underlying these 
effects are unknown. Therefore, the project goal is to determine the role of 
PFKFB3/iPFK2 in overnutrition related adipose tissue and intestine inflammatory 
responses and insulin resistance. The central hypothesis of this project is that 
PFKFB3/iPFK2 coordinates metabolic and inflammatory responses in adipose tissue and 
intestine to modulate the generation of metabolism-regulator factors, and thereby brings 
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about inter-tissue effects to regulate systemic metabolic hemostasis. The significance of 
this work is the identification of the mechanisms underlying the pathogenesis of obesity 
and diabetes so that novel therapeutic targets can be found to treat obesity and diabetes. 
The general approach used to test the central hypothesis includes measurement of 
changes in biomarkers of metabolism and inflammation using loss-of-function of 
PFKFB3/iPFK2 and/or gain-of-function of PFKFB3/iPFK2 in mice. The approach is 
innovative because it is unique to use PFKFB3/iPFK2-knockout mice model and 
PFKFB3/iPFK2-adipocyte-specific overexpressing mice model. The predicted outcome 
is that PFKFB3/iPFK2, although contributing to adiposity, protects against diet-induced 
adipose tissue and intestine inflammatory responses, and improves insulin sensitivity. 
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CHAPTER II 
 
LITERATURE REVIEW 
 
METABOLIC SYNDROME, OBESITY, AND TYPE 2 DIABETES 
            Leading causes of death altered in US compared to a hundred years ago. The top 
10 causes of death shifted from infection-related diseases such as pneumonia, influenza, 
tuberculosis and enteritis to nutrition-related diseases such as heart disease, cancer, 
stroke, diabetes [1]. Diabetes became the seventh leading cause of death, as shown in 
Figure 1. In the US, type 2 diabetes accounts for 95% of all diabetes cases, and is 
associated with obesity. Type 2 Diabetes Mellitus (T2DM) is recognized to be a potential 
killer, because it can be latent for many years and neglected by people.  Millions of 
people may have undiagnosed diabetes, and millions of people have pre-diabetes.  In 
recent decades, more and more adolescences and children are diagnosed with type 2 
diabetes [2].  
             Metabolic syndrome is a condition with insulin resistance and other metabolic or 
vascular disorders. The characteristic features of metabolic syndrome, as shown in 
Figure 2, include central obesity, insulin resistance, hypertension, dyslipidemia, 
atherosclerosis, and certain forms of cancers [3-5]. Overnutrition or obesity has been 
considered one of causing factors of metabolic syndrome. Weight loss due to a very-
low-calorie-diet can improve several aspects of metabolic syndrome such as reduction of 
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Figure 1. Leading Causes of Death in the US, 1900 vs. 2009. [1] 
 
 
 
 blood pressure, glucose, triglycerides and cholesterol [6]. Insulin is an important 
hormone that facilitates the uptake and metabolism of glucose in muscle and adipose 
tissue. Insulin resistance is a physiological condition that normal insulin function is 
impaired and becomes less effective to lower blood glucose. Central obesity, physical 
inactivity and genetic factors are main reasons leading to the development of insulin 
resistance. Insulin resistance has been considered an important factor developing 
metabolic syndrome and connecting many of the features of metabolic syndrome [7].  
However, recent studies suggest that inflammation is associated with the pathogenesis of 
metabolic syndrome [8], as shown in Figure 3. Nutrients overload, physical inactivity, 
and/or genetic factors result in obesity, which is characterized by a low-grade chronic 
inflammation. The later is displayed by increased production of inflammatory cytokines 
such as Tumor Necrosis Factor Alpha (TNFα) and Interleukin 6 (IL-6) via enhancing the 
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generation of Reactive Oxygen Species (ROS) and stimulating Nuclear Factor-κB (NF-κB) 
signal pathway[9]. Inflammation has been found to cause insulin resistance, atherosclerosis, 
and certain forms of cancers. Insulin resistance also exacerbates inflammatory responses, 
which forms a vicious cycle and leads to metabolic syndrome [8-10].  
 
INFLAMMATION: A CAUSAL FACTOR OF OBESITY-RELATED INSULIN 
RESISTANCE AND DIABETES 
            Increasing plasma levels of inflammatory markers such as TNFα, IL-6, leptin, 
and C-Reactive Protein (CRP) in overweight and obese animals and subjects indicate 
that obesity can be considered as a low-grade systemic inflammatory disease [11-14]. 
White Adipose Tissue (WAT) of obese human and animals is characterized by elevated 
production and secretion of inflammatory factors including TNFα and IL-6 [15, 16]. 
Macrophage infiltration in adipose tissue due to adipose tissue dysfunction is suggested 
to produce prominent source of pro-inflammatory cytokines in adipose tissue [17, 18]. 
Inflammatory factors produced and secreted from both adipocytes and macrophages 
have effects not only on adipose physiological functions, but also on other organs such 
as liver and muscle, and contribute to the pathogenesis of insulin resistance [19, 20].  
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Figure 2. Characteristic Features of Metabolic Syndrome. 
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Figure 3. Pathogenesis of Metabolic Syndrome.[8] 
 
 
 
            Many studies suggest that anti-inflammatory approaches are effective in terms of 
reversing systemic insulin resistance and improving systemic metabolic homeostasis 
[21]. Exercise, a way to improve insulin sensitivity, can enhance anti-inflammatory 
effects via increasing levels of anti-inflammatory cytokines and reducing levels of pro-
inflammatory cytokines. For example, IL-6 produced by muscle during exercise 
stimulates the production of anti-inflammatory factors such as Interleulik-1 receptor 
antagonist (IL-1ra) and Interleukin-10 (IL-10), which can inhibit the production of 
TNFα [22, 23]. In addition, exercise suppresses the production of inflammatory 
monocytes such as CD14+ and CD16+ cells [24]. Insulin-sensitizing drugs — 
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thiazolidinediones (TZDs) such as troglitazone, rosiglitazone and pioglitazone, have 
anti-inflammatory effects via activation of PPARγ and suppression of inflammatory 
cytokines [25-27]. Metformin, an anti-diabetic drug, exerts anti-inflammatory effects by 
inhibition of NFκB, TNFα and IL-6 production via blockade of Phosphatidylinositol-3 
Kinase (PI3K)-Akt pathway and PI3K-dependent 5’ Adenosine Monophosphate-
activated Protein Kinase (AMPK)  phosphorylation [28-30]. Some nutrients have impact 
on insulin action. Omega-3 fatty acids such as Docosahexaenoic Acid (DHA) and 
Eicosapentaenoic Acid (EPA) exhibit anti-inflammatory effects and enhance insulin 
sensitivity via stimulation of G Protein-coupled Receptor 120 (GPR120) [31, 32].  Anti-
oxidant vitamins (Vitamin E and C) exhibit anti-inflammatory effects and improve 
insulin sensitivity by inhibition of oxidative stress [33]. Dietary flavonoids, which are 
ubiquitous in plants such as nuts, seeds, fruits and vegetables, have antioxidant and anti-
inflammatory activities which provide benefits on chronic inflammatory diseases [34]. 
             Elevated serum levels of inflammatory markers such as CRP, IL-6, IL-1, and 
white cell count are associated with T2DM [35]. Some T2DM prevention programs 
including metformin therapy and lifestyle intervention significantly reduce inflammatory 
markers [36]. Proinflammatory cytokines derived from adipose tissue such as IL-6 and 
TNFα  have been shown to play a key role in causing insulin resistance [19, 37]. 
Therefore, it is evident that there is a link between inflammation and pathogenesis of 
insulin resistance and T2DM.  
            The mechanisms underlying the link between the inflammatory response and the 
pathogenesis of insulin resistance is involved several molecule pathways, as shown in 
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Figure 4. In normal insulin action, insulin binds to insulin receptor and triggers PI3K-
Akt pathway via insulin receptor substrate (IRS). Akt is phosphorylated and activated. 
Active Akt mediates many downstream signals, and targets a series of substrates that 
govern cell metabolism and proliferation [38-40]. For example, Akt phosphorylation 
mediates translocation of Glucose Transporter 4 (GLUT4) from cytosol to membrane. 
GLUT4 is an important transporter for glucose uptake in adipocytes and muscle cells 
[39]. Blockade of IRS function impairs insulin signal pathway. Therefore, IRS is a 
crucial signal molecule for insulin action. Inflammatory cytokine, ROS and lipid 
products activate c-Jun N-terminal Kinases (JNK) and result in serine phosphorylation of 
IRS-1 and 2, thus inhibiting insulin signaling. Activation of IκB Kinase (IKK) 
phosphorylates IκBα which releases NF-κB to the nucleus. NF-κB triggers a series of 
transcriptional events to produce inflammatory cytokines. Therefore, many more 
inflammatory cytokines activate JNK and IKK, exacerbating insulin resistance. JNK also 
controls the expression of inflammatory genes through transcription factor Activator 
Protein 1(AP-1). Peroxisome proliferator-activated receptor (PPAR) and Liver X 
Receptor (LXR) families transcript genes of metabolism inhibit inflammatory activity. 
Fatty Acid Binding Proteins (FABPs) block PPAR- and LXR-mediated transcriptional 
events through regulating lipids activities [9, 41, 42].  
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Figure 4. Molecular Pathways Linking Inflammatory Response and Insulin Action. 
[9, 41] 
 
 
 
ADIPOSE TISSUE FUNCTION AND INFLAMMATION 
            White adipose tissue is an important metabolic organ, which stores energy when 
energy balance is positive and releases energy when energy balance is negative [43, 44]. 
In the process of storing energy, Free Fatty Acids (FFAs) are generated as the products 
of Triglyceride (TG) hydrolysis during delivery of both dietary fats in the form of 
chylomicrons and endogenous fats in the form of very low density lipoproteins in 
 11 
 
 
response to feeding. FFAs, along with glycerol as additional products of triglyceride 
hydrolysis, are then transported into adipocytes via a transport complex. Inside 
adipocytes, free fatty acids are re-esterified and the resultant triglycerides are stored in 
lipid droplets.  
            Adipose tissue is also an endocrine organ, whose endocrine functions tightly 
control systemic metabolic homeostasis. In fact, the balance between the release of pro-
hyperglycemic factors such as FFAs and resistin and anti-hyperglycemic factors such as 
adiponectin, as well as the production of proinflammatory cytokines such as tumor 
necrosis factor alpha (TNFα) and interleukin 6 (IL-6) from both adipocytes and adipose 
tissue macrophages and other immune cells, determine insulin sensitivity and glucose 
metabolism locally in adipose tissue and distally in liver and skeletal muscle [45-48]. Of 
significance, the endocrine function of adipose tissue is tied closely with adipocyte 
glucose and lipid metabolism. 
            Adipose tissue has an important relevance to metabolic disease. Much evidence 
suggests that adipose tissue dysfunction is a major causing factor of insulin resistance 
[49-51]. White adipose tissue dysfunction is prominently characterized by decreased 
capability of fat storage which results in excessive energies (glucose and fatty acids) 
likely because nutrients cannot be converted to TG for storage in fat cells, rather stay in 
circulation. Organs are exposed in high glucose and fatty acids, leading to decrease 
insulin signal pathway or insulin resistance. Meanwhile, accumulation of TG in other 
organs destroys functions of organs, inducing various metabolic diseases. For example, 
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accumulation of fat in liver causes fatty liver which can result in Steatohepatitis and 
even cirrhosis [52, 53] 
            Many studies showed that inflammation is one of characters in metabolic 
dysregulation of white adipose tissue [16, 54-58]. Overnutrition causes excessive 
accumulation of TG in fat cells, which enlarges their sizes. Once the fat cells 
continuously enlarge, functions of fat cells are impaired. Fat cells release many 
cytokines such as TNFα and Monocyte Chemotactic Protein-1 (MCP-1), which attracts 
macrophages and promotes macrophage infiltration in adipose tissue, as shown in Figure 
5. Inside adipose tissue, macrophages release many more inflammatory factors that, in 
turn, impair insulin signaling in adipose tissue and promote insulin resistance. Because 
of insulin resistance in adipose tissue, fat cells cannot normally intake and metabolize 
glucose and store energy. This causes metabolic dysregulation of adipose tissue, which 
contributes to systemic metabolic dysregulation and insulin resistance [18, 59]. 
 
INTESTINAL FUNCTION AND INFLAMMATION 
            There are many studies focusing on metabolic disorders in liver, adipose tissue 
and skeletal muscle. However, little studies investigated the role of the intestine in 
overnutrition-related metabolic disorders. Intestine is the organ for digestion, absorption 
and assimilation of nutrients. Physiologically, nutrients absorbed by intestine, along with 
a number of nutritional and hormonal signals, are delivered to both central and 
peripheral tissues in response to feeding. This leads to appropriate regulation of nutrient 
metabolism in key metabolic tissues such as liver, adipose tissue, and skeletal muscle to 
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Figure 5. Adipose Tissue Inflammation and Macrophage Infiltration in Obesity.[16] 
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maintain systemic metabolic homeostasis and insulin sensitivity [60, 61]. For example, 
incretin hormones secreted by intestine facilitate glucose uptake by muscle and suppress 
the production of glucose in liver [62, 63]. The hormones secreted by the intestine can 
control not only the intestinal motility and satiety but also the glucose homeostasis [64]. 
In HFD induced obesity and insulin resistance mouse models, many genes related to 
lipid metabolism are altered in the small intestine, and are associated with insulin 
resistance [65]. Pathologically, nutrient overload disturbs glucose and lipid metabolism 
and triggers the inflammatory response in intestine. For example, feeding a High-Fat 
Diet (HFD) to mice activates NF-κB activity in intestine cells including epithelial cells, 
immune cells, and endothelial cells of small intestine[66], which appears to contribute to 
HFD-induced insulin resistance and adiposity. 
             Intestine also hosts microbes, whose composition, when altered by overnutrition, 
contributes to increased intestine inflammatory response and the development of 
systemic insulin resistance [66-69]. Failure to maintain the balance causes impairment of 
intestinal homeostasis, even systemic homeostasis [70]. Under overnutrition, gut 
microbiota are modified and promote the secretion of proinflammatory cytokines that are 
associated with the development and progression of insulin resistance and metabolic 
disorder [66, 71]. Mechanisms of the control of inflammation by microbiota could be 
due to that changes in microbiota increase intestinal permeability [72, 73]. 
            At this point, little is known about how glucose and lipid metabolism is 
orchestrated to regulate intestine inflammatory response. To understand the link between 
intestine nutrient metabolism and the inflammatory response in intestine is of particular 
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importance to a better understanding of the patho-physiology of overnutrition-associated 
insulin resistance and inflammatory intestine diseases. 
 
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR γ (PPARγ) 
            Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors. There 
are three PPAR isotypes are found: α, β, and γ [74]. PPARα is highly expressed in the 
liver and brown adipose tissue. PPARβ is expressed most in kidney, heart and gut. 
PPARγ is mainly expressed in adipose tissue [74, 75]. Many researches have shown that 
PPARγ activated by TZDs effectively improves systemic insulin sensitivity and lowers 
plasma glucose levels in both human patients and rodent models of type 2 diabetes [76-
82].  In nucleus, PPARγ forms a heterodimer with the Retinoid X Receptor (RXR). 
When TZDs binds to PPARγ, a structure change promotes the binding of the PPARγ-
RXR complex to PPARγ Response Elements (PPREs) in target genes and changes of the 
transcription of these genes [83-85]. PPREs are found in many genes involved in glucose 
metabolism and lipid metabolism, such as GLUT4 transporter, glucokinase, fatty acids 
transporter protein, lipoprotein lipase, and Fatty Acyl-CoA Synthase (FAS) [85, 86].  
            Because TZDs are effective in liver- or muscle-specific PPARγ-deficient mice 
[87, 88] but not in adipose tissue-deleted mice [89] and adipose-specific PPARγ-
deficient mice [90], adipose tissue has been considered as the primary target site for the 
anti-diabetic effect of PPARγ activation [91, 92]. Further investigations have suggested 
two adipose tissue-based mechanisms to largely explain the anti-diabetic effects of 
PPARγ activation [45, 81], as shown in Figure 6. In the first mechanism, PPARγ 
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activation by TZDs appropriately alters the expression of adipocyte genes that are 
involved in lipogenesis and TG synthesis to increase the capacity of fat storage in 
adipose tissue [93-96]. This leads to reduction of the circulating levels of FFAs and 
thereby reversal of FFAs-induced insulin resistance by the effect on systemic glucose 
metabolism, including suppression of hepatic glucose output and increasing glucose 
uptake by muscle. In the second mechanism, PPARγ activation by TZDs suppresses the 
adipose tissue inflammatory response [58, 97] and appropriately regulates adipokine 
expression [81, 98, 99]. This improves adipose tissue function, which in turn brings 
about the insulin-sensitizing effect [81]. However, the molecular link between the two 
mechanisms remains to be elucidated.  
            Upon activation of PPARγ, a number of PPARγ target genes are altered to 
promote fat storage in adipose tissue [100-103]. For example, TZDs stimulate the 
expression of Glycerol Kinase (GyK), which increases triglyceride synthesis in 
adipocytes by providing glycerol 3-phosphate as a key substrate [100]. Similarly, PPARγ 
activation stimulates the expression of the cyto-solic isoform of Phosphoenolpyruvate 
Carboxykinase (PEPCK) in adipocytes [101, 102]. This increases glyceroneogenesis and 
provides another way to synthesize glycerol 3-phosphate and consequently triglycerides 
in adipocytes/adipose tissue [104, 105]. At this point, although the stimulatory effect of  
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Figure 6. Mechanisms for Anti-diabetic Effects of PPARγ Activation. [99] 
 
 
 
PPARγ activation on GyK and PEPCK expression is increasingly documented, the 
involvement of GyK and/or PEPCK in the antidiabetic effect of PPARγ activation 
requires further exploration [106, 107]. Furthermore, there are no published data to 
address whether or not GyK and/or PEPCK are involved in the anti-inflammatory effect 
of PPARγ activation. In response to TZDs, the expression of several proinflammatory 
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genes is decreased in the adipose tissue in both rodents and human patients with type 2 
diabetes [95, 108]. Further, PPARγ activation in both adipose tissue macrophages and 
adipocytes contributes to the suppression of the adipose tissue inflammatory response 
[97, 109]. To date, mediators that are involved in the effect of PPARγ activation on 
adipocyte inflammatory response are largely unknown. 
 
PFKFB3/iPFK2 
PFKFB3 is the gene that encodes for the inducible 6-phosphofructo-2-kinase 
(iPFK2) that is highly expressed in adipose tissue [110]. PFKFB3/iPFK2 generates 
fructose-2,6-bisphosphate (F26P2), which in turn activates 6-phosphofructo-1-kinase 
(6PFK1) to enhance glycolysis [111-113]. This effect is involved in adipocyte 
lipogenesis and triglyceride synthesis [110].   
As shown in Figure 7, glucose uptake following insulin-stimulated GLUT4 
translocation provides sufficient substrate that can be metabolized through glycolysis to 
produce glycerol-3-phosphate. Moreover, adipocyte glycolysis also generates pyruvate 
whose further metabolism in mitochondrial provides acetyl-CoA. The latter is used for 
generation free fatty acids through lipogenesis, and then triglycerides. In adipocytes, 
hexokinase catalyzes glucose phosphorylation. This step, however, is not a rate-limiting 
step. Instead, generation of F1,6P2 from F6P is the rate-limiting step. F2,6P2 activates 
6PFK1 to enhance glycolysis in adipocytes. iPFK2, encoded by PFKFB3 [110] is the 
enzyme that generates F2,6P2. Given this, glycolysis is a key to storing energy in 
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adipocytes. In support of this, iPFK2 is necessary for an increase in fat storage in white 
adipose tissue and in fat deposition in adipocytes. 
 
 
Figure 7. PFKFB3/iPFK2 Coordinates Adipocyte Glucose and Lipid 
Metabolism.  
 
 
 
 
 
However, it is unknown whether the metabolic properties of PFKFB3/iPFK2 are 
related to the regulation of adipose tissue function, in particular adipose tissue 
inflammatory response. The present study provides evidence to support a novel role for 
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PFKFB3/iPFK2 in regulating diet-induced systemic insulin resistance and adipose tissue 
inflammatory response in a manner independent of adiposity. 
 
SUMMARY 
            Diabetes became the seventh leading cause of death in the US. Additionally, 95% 
of diabetes is type 2 diabetes, which is mostly associated with obesity. Millions of 
people may have undiagnosed diabetes, and millions of people have pre-diabetes. Type 2 
diabetes is characterized by insulin resistance. Nutrients overload, physical inactivity, 
and/or genetic factors result in obesity; this is characterized by a low-grade chronic 
inflammation. Inflammation contributes to insulin resistance. The later also exacerbates 
inflammatory response.  
            Mechanisms underlying the link between the inflammatory response and the 
pathogenesis of insulin resistance are associated with several molecule pathways. In 
normal insulin action, insulin binds to insulin receptor and triggers PI3K-Akt pathway 
via insulin receptor substrate (IRS). Inflammatory cytokines, ROS and lipid products 
activate c-Jun N-terminal Kinases (JNK) and result in serine phosphorylation of IRS-1 
and 2 which inhibits insulin signaling. Activation of IκB Kinase (IKK) phosphorylates 
IκBα which releases NF-κB to nucleus. NF-κB triggers a series of transcriptional events 
to produce inflammatory cytokines. Therefore, many more inflammatory cytokines 
activate JNK and IKK, which exacerbate insulin resistance.  
            Peroxisome proliferator-activated receptor γ (PPARγ) is nuclear receptors whose 
activation by TZDs effectively improves systemic insulin sensitivity and lowers plasma 
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glucose levels. In response to TZDs, the expression of several proinflammatory genes is 
decreased in the adipose tissue in both rodents and human patients with type 2 diabetes. 
Further, PPARγ activation in both adipose tissue macrophages and adipocytes 
contributes to the suppression of the adipose tissue inflammatory response. However, 
mediators that are involved in the effect of PPARγ activation on adipocyte inflammatory 
response are largely unknown. 
PFKFB3 is the gene that encodes for the inducible 6-phosphofructo-2-kinase 
(iPFK2) that is highly expressed in adipose tissue. PFKFB3/iPFK2 enhances glycolysis 
which is involved in adipocyte lipogenesis and triglyceride synthesis. iPFK2 has been 
found to be necessary for an increase in fat storage in adipose tissue and in fat deposition 
in adipocytes. White adipose tissue is an important metabolic organ, as well as an 
endocrine organ. Adipose tissue dysfunction has been found to be the causing factor of 
inducing and developing insulin resistance. Inflammation is one of characters in 
metabolic dysregulation of white adipose tissue. PFKFB3 may play a role in adipose 
tissue function and inflammation. Recently, it was shown that PFKFB3 is also expressed 
in small intestine. Intestine is the organ for digestion, absorption and assimilation of 
nutrients. Nutrient overload disturbs glucose and lipid metabolism and triggers the 
inflammatory response in intestine. PFKFB3 regulates glucose and lipid metabolism, 
and appears to be associated with intestine inflammation.  
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CHAPTER Ш 
 
THE ROLE OF PFKFB3/iPFK2 IN MOUSE ADIPOSE TISSUE METABOLISM, 
INFLAMMATORY RESPONSE, AND SYSTEMIC INSULIN RESISTANCE*  
 
INTRODUCTION 
 
Many studies demonstrated that overnutrition is associated with adiposity and 
systemic insulin resistance. For example, feeding an HFD to rats for 10 weeks causes a 
significant increase in visceral fat mass, which is accompanied by a decrease in systemic 
insulin sensitivity [114]. Similarly, after a feeding of HFD for 20 weeks, two different 
strains of wild-type mice gain a significant increase in fat mass, which is associated with 
systemic insulin resistance and glucose intolerance [115]. A recent study even indicates 
that feeding a HFD to mice for only 6 weeks is sufficient to induce adiposity and 
systemic insulin resistance [116]. Furthermore, as documented in mice lacking the 
myotonic dystrophy protein kinase, a larger augmentation in adiposity is accompanied 
___________   
* Reprinted with permission from Huo, Y., Guo, X., Li, H., Wang, H., Zhang, W., Wang, 
Y., Zhou, H., Gao, Z., Telang, S., Chesney, J., Chen, Y.E., Ye, J., Chapkin, R.S., and Wu, 
C. Disruption of inducible 6-phosphofructo-2-kinase ameliorates diet-induced adiposity 
but exacerbates systemic insulin resistance and adipose tissue inflammatory response. J 
Biol Chem, 2010. 285: 3713-3721. Copyright 2010 by the American Society for 
Biochemistry and Molecular Biology and from Huo, Y., Guo, X., Li, H., Xu, H., Halim, 
V., Zhang, W., Wang, H., Fan, Y., Ong, K.T., Woo, S., Chapkin, R.S, Mashek,D.G., Chen, 
Y., Dong, H., Lu, F., Wei, L., Wu. C. Targeted overexpression of inducible 6-
Phosphofructo-2-kinase in adipose tissue increases fat deposition but protects against 
diet-induced insulin resistance and inflammatory response. J Biol Chem, 2012. 287(25): 
21492-21500. Copyright 2012 by the American Society for Biochemistry and Molecular 
Biology. 
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by a greater increase in the severity of systemic insulin resistance [116]. Because of this, 
adiposity has been generally viewed as an important contributor of systemic insulin 
resistance [46, 116-119]. On the other hand, reducing adiposity has been considered as 
an effective way to reverse systemic insulin resistance [93, 114]. However, adiposity is 
not necessarily associated with systemic insulin resistance. This is particularly true in 
genetically modified mice and in mice treated with pharmacological agents [97, 120-
123]. Following the investigation into the insight of altered systemic insulin sensitivity, 
it has been suggested that adipose tissue dysfunction is far more important than adiposity 
in terms of causing systemic insulin resistance [45, 81, 97, 124].   
Mounting evidence points to a pivotal role for overnutrition-related inflammation 
in causing adipose tissue dysfunction, and thereby systemic insulin resistance. In mice 
fed an HFD, chronic low-grade inflammation in adipose tissue is evident and 
characterized by an increase in macrophage infiltration and proinflammatory cytokine 
production [125, 126]. This brings about adipose tissue dysfunction, demonstrated by an 
increase in the production pro-hyperglycemic factors such as free fatty acids and resistin 
and a decrease in the production of anti-hyperglycemic factors such as adiponectin [45-
48]. These changes, along with increased production of proinflammatory cytokines such 
as tumor necrosis factor α (TNFα) and interleukin 6 (IL-6) from both adipocytes and 
adipose tissue macrophages, impair insulin signaling in insulin-sensitive tissues 
including the liver and skeletal muscle, leading to systemic insulin resistance [127-132]. 
In contrast, treatment with thiazolidinediones ameliorates adipose tissue inflammation, 
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which in turn contributes, at least in part, to the reversal of diet-induced adipose tissue 
dysfunction and systemic insulin resistance [97, 108]. For this reason, adipose tissue 
inflammation is of particular importance to the regulation of systemic insulin sensitivity.   
            PFKFB3 is the gene that encodes for the inducible 6-phosphofructo-2-kinase 
(iPFK2) that is highly expressed in adipose tissue [110]. PFKFB3/iPFK2 generates 
fructose-2,6-bisphosphate (F26P2), which in turn activates 6-phosphofructo-1-kinase 
(6PFK1) to enhance glycolysis [111, 112]. This effect is involved in adipocyte 
lipogenesis and triglyceride synthesis [110]. PFKFB3 is decreased in adipose tissue of 
KKAy mice which is a model of type 2 diabetes and in PPARγ2-deficient mice which is 
a model of insulin resistance. However, it is unknown how the metabolic properties of 
PFKFB3/iPFK2 are related to the regulation of adipose tissue function, in particular 
adipose tissue inflammatory response. 
 
MATERIALS AND METHODS 
 
Animal Experiments  
            Homozygous disruption of PFKFB3/iPFK2 is embryonic lethal [133]. Thus, 
PFKFB3+/– mice, generated as previously described [133], were used in the present 
study. Adipocyte-specific PFKFB3/iPFK2 overexpression mice were also generated in 
this study [134, 135]. Wild-type littermates (C57BL/6J background) were used as the 
control. All mice were maintained on a 12:12-h light-dark cycle (lights on at 06:00). At 
the age of 5 - 6 weeks, mice were fed an HFD (60% fat calories, 20% protein calories, 
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and 20% carbohydrate calories) or low-fat diet (LFD) (10% fat calories, 20% protein 
calories, and 70% carbohydrate calories) for 12 weeks. Both diets are products of 
Research Diets, Inc (New Brunswick, NJ) and contain the same of amount of casein, L-
cystein, cellulose, soybean oil, and minerals. However, the HFD contains much more 
lard and maltodextrin but much less sucrose and none corn starch compared to the LFD. 
During the 12-week feeding period, body weight and food intake of the mice were 
recorded every 4 days. After the feeding regimen, mice were fasted for 4 h before 
sacrifice for collection of blood and tissue samples [135-137]. After anesthesia with 
ketamine/Xylene (100 mg/kg / 10 mg/kg body weight) via intraperitoneal injection, the 
abdomen was quickly opened. Epididymal, mesenteric, and perinephric fat depots were 
dissected and weighed as visceral fat content [136]. After weighing, adipose tissue 
samples were either fixed and embedded for histological and immunohistochemical 
analyses or frozen in liquid nitrogen and then stored at – 80 °C for further analyses. 
Some mice were fasted similarly and used for insulin and glucose tolerance tests and 
insulin signaling analyses. All study protocols were reviewed and approved by the 
Institutional Animal Care and Use Committee of Texas A&M University. 
 
Determination of PFKFB3 mRNA, iPFK2 Amount, and F26P2 level  
            PFKFB3 mRNA and iPFK2 amount in the adipose tissue were determined using 
real-time RT-PCR and Western blot, respectively, as described below. Similarly, the 
amount of iPFK2 in the brown adipose and liver tissues was determined using Western 
blot. The levels of F26P2 were measured using the 6PFK1 activation method [135]. 
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Measurement of Adipose Tissue Lipolysis 
            The assays were conducted in the same ways as described by Berger and 
Haemmerle [138, 139]. Briefly, freshly isolated adipose tissue samples were washed 
several times with PBS and incubated in a final volume of 1 ml high glucose Dulbecco’s 
modified Eagle’s medium (DMEM) containing 2% fatty acid–free BSA with or without 
10 μM isoproterenol at 37°C for 3 h. Aliquots of the medium were collected hourly to 
quantify glycerol content using metabolic kits (BioVision, Mountain View, CA). 
Lipolysis was estimated as the efflux of glycerol.  
 
Insulin and Glucose Tolerance Tests  
            Mice were fasted for 4 h and received an intraperitoneal injection of insulin (1 
U/kg) or D-glucose (2 g/kg). For insulin tolerance tests, blood samples (5 µl) were 
collected from the tail vein before and at 15, 30, 45, and 60 min after the bolus insulin 
injection. Similarly, for glucose tolerance tests, blood samples were collected from the 
tail vein before and at 30, 60, 90 and 120 min after the glucose bolus injection [137].  
 
Measurement of Plasma Metabolic Parameters  
            The levels of plasma glucose, triglycerides, and free fatty acids were measured 
using metabolic assay kits (Sigma, St. Louis, MO and BioVision, Mountain View, CA). 
The levels of plasma insulin and leptin were measured using ELISA kits (Crystal Chem 
Inc., Downers Grove, IL).  
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 Histological and Immunohistochemical Analyses of Adipose Tissue  
            The paraffin-embedded adipose tissue blocks were cut into sections of 5 µm 
thickness and stained with H&E. In addition, the sections were stained for the expression 
of F4/80 with rabbit anti-F4/80 (1:100) (AbD Serotec, Raleigh, NC) as previously 
described [125, 140]. The fraction of F4/80-expressing cells for each sample is 
calculated as the sum of the number of nuclei of F4/80-expressing cells divided by the 
total number of nuclei in sections of a sample. Six fields per slide were included, and a 
total of 4 to 6 mice per group were used.  
 
Isolation of Stromal Vascular Cells (Macrophages) and Adipocytes from Adipose 
Tissue  
            Stromal vascular cells (SVCs) and adipocytes were isolated using the collagenase 
digestion method as previously described [97]. After digestion and centrifugation, the 
pelleted cells were collected as SVCs and the floating cells were harvested as 
adipocytes.  
 
Cell Culture and Treatment  
            3T3-L1 cells were maintained in high glucose DMEM supplemented with 10% 
fetal bovine serum (FBS), 100U/ml penicillin and 100μg/ml streptomycin. To 
differentiate 3T3-L1 cells, the 2 d post-confluent cells were incubated in growth medium 
supplemented with 10 μg/ml insulin, 1 μM dexamethasone, and 0.5 mM 3-isobutyl-1-
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methyl-xanthine for 48 h, followed by incubation for an additional 6 – 8 d in growth 
medium supplemented with 10 g/ml insulin. To knock down PFKFB3/iPFK2, 
predifferentiated 3T3-L1 cells were transfected with the plasmid containing shRNA 
against mouse PFKFB3 (iPFK2-KD) (OriGene, Rockville, MD) with Lipofectamine™ 
2000 Transfection Reagent (Invitrogen, Carlsbad, CA) following the manufacturer’s 
protocol. Similarly, predifferentiated 3T3-L1 cells were transfected with shRNA vector 
(iPFK2-Ctrl) and served as the control. To overexpress PFKFB3/iPFK2, 
predifferentiated 3T3-L1 cells were transfected with plasmid containing the cDNA of 
iPFK2. As a control, predifferentiated 3T3-L1 cells were transfected with empty vector. 
After transfection for 24 h, the cells were induced for differentiation for 6 – 8 d. 
Thereafter, iPFK2-KD adipocytes, iPFK2-OX adipocytes, two iPFK2-Ctrl adipocytes, as 
well as un-transfected adipocytes were used for the following assays. Some transfected 
predifferentiated 3T3-L1 cells were selected with puromycin (5 μg/ml) to establish 
stable cell lines for further analyses.  
            To verify PFKFB3/iPFK2 knockdown or overexpression, cell lysates were 
prepared and used to determine iPFK2 amount using Western blot. To determine the rate 
of glucose incorporation into lipid, each well (6-well plate) of the cells was incubated 
with DMEM supplemented with 1 μCi [U-14C]-glucose for 24 h as previously described 
[141]. After sequential extraction with 30% KOH, 95% ethanol, 9 M H2SO4, and 
petroleum ether, the amount of [14C]-lipids was quantified using a Beckman liquid 
scintillation counter. To quantify adipocyte lipid content, the cells were stained with Oil 
Red O. The lipid-associated dye was extracted with isopropanol for 15 min. The optical 
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density (OD) of the extraction solution was measured using spectrophotometer at 510 nm 
[120]. To determine the status of adipocyte oxidative stress, the cells were treated with 
palmitate (250 μM) or vehicle for 24 h and used to measure the production of reactive 
oxygen species (ROS) using the nitroblue tetrazolium (NBT) assay as previously 
described [142]. Additionally, after differentiation, stable adipocytes were treated with 
or without palmitate (250 μM) for 24 h. In the last hour of treatment, 100 μM etomoxir 
(an inhibitor of carnitine palmitoyltransferase-1, CPT1) or 10 mM N-acetyl-L-cysteine 
(an antioxidant) was added, and the production of ROS was determined. To determine 
adipocyte expression of adipokines and proinflammatory cytokines, the total RNA of the 
cells was prepared and used for real-time RT-PCR. To determine changes in 
inflammatory signaling, the cells were treated with or without lipopolysaccharides (LPS, 
100 ng/ml) for 1 h prior to harvest. Cell lysates were prepared and used to measure the 
levels and phosphorylation states of JNK and NFκB p65 using Western blots. To 
determine changes in insulin signaling, the cells were treated with or without insulin 
(100 nM) for 30 min prior to harvest. Cell lysates were prepared and used to measure the 
levels and phosphorylation state of Akt using Western blots. 
 
RNA Isolation, Reverse Transcription, Real-time PCR, and Microarray  
            The total RNA was isolated from frozen tissue samples and cultured/isolated 
cells. RNA isolation and real-time RT-PCR were conducted as previously described 
[137]. The mRNA levels were analyzed for PFKFB3, F4/80, TNFα, IL-6, resistin, 
adiponectin, peroxisome proliferator-activated receptor alpha (PPARα), PPAR gamma 
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co-activator 1 (PGC1), and Carnitine palmitoyltransferase I (CPT1) in adipose tissue 
samples and/or cell samples. Additionally, the RNA of adipose tissue samples from 
HFD-fed PFKFB3+/– and wild-type littermates were used for mouse Agilent 44K 
microarray using methods as previously described [143, 144].      
 
Western Blots  
            Lysates were prepared from frozen tissue samples and cultured cells. Western 
blots were conducted as previously described [136, 137]. The levels of iPFK2, Akt1/2, 
phospho-Akt (Ser473), JNK, phospho-JNK, NFκB p65 and phospho-p65 were analyzed. 
 
Statistical Methods  
            Numeric data are presented as means ± SE (standard error). Statistical 
significance was assessed by unpaired, two-tailed ANOVA or Student’s t test. 
Differences were considered significant at the two-tailed P < 0.05.  
 
RESULTS OF ANIMAL STUDIES 
 
The Distribution of PFKFB3/iPFK2  
            The expression profile of PFKFB3/iPFK2 was determined in various tissues in 
wild-type mice. Among the key tissues that are involved in the regulation of systemic 
insulin sensitivity and metabolic homeostasis, PFKFB3/iPFK2 is expressed at high 
levels in the adipose tissue and expressed at very low levels in the liver and muscle 
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(Fig.8). These data suggest that PFKFB3/iPFK2-associated metabolic changes are due 
primarily to alteration of PFKFB3/iPFK2 in the adipose tissue. 
 
The Confirmation of PFKFB3+/– Mice 
            Homozygous disruption of PFKFB3/iPFK2 is embryonic lethal [133]. Thus, 
PFKFB3+/– mice were generated for the present study. Disruption of PFKFB3/iPFK2 
was confirmed using PCR (Fig. 9). 
 
 
 
 
Figure 8. The Distribution of PFKFB3/iPFK2. Wild-type C57BL/6J mice were used 
for analyses. PFKFB3 is abundantly expressed in epididymal (Epi) and inguinal (Ing) 
white adipose tissue. BAT, brown adipose tissue. Data are means ± SE, n = 4. †† P < 
0.01 vs. liver. 
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Figure 9. The Confirmation of PFKFB3+/– Mice. PCR analyses of mouse genomic 
DNA using an exon 2-specific primer with a neomycin-specific primer (+/–, 
heterozygous) or an exon 3-specific primer (+/+, wild-type). 
 
 
 
Changes of PFKFB3 mRNA and iPFK2 Amount and Activity in PFKFB3+/– Mice         
            PFKFB3+/– mice were used to examine changes in PFKFB3 mRNA and iPFK2 
amount and activity in the adipose tissue. Disruption of PFKFB3/iPFK2 resulted in 
decreased PFKFB3/iPFK2 expression at both the mRNA and protein levels (Fig. 10 A, B 
and C). Compared to that in epididymal adipose tissue, the amount of iPFK2 was less 
abundant in the brown adipose tissue (Fig.10 B and C). Because PFKFB3/iPFK2 
determines the production of F26P2, the levels of adipose tissue F26P2 were quantified as 
a direct indicator of iPFK2 activity. In PFKFB3+/– mice, the levels of adipose tissue 
F26P2 were significantly lower than those in wild-type littermates (Fig. 10 D). 
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Disruption of PFKFB3/iPFK2 Blunts HFD-induced Weight Gain 
            Feeding an HFD to mice induces obesity [115, 124]. To determine the effect of 
PFKFB3/iPFK2 disruption on diet-induced obesity, PFKFB3+/– mice and wild-type 
littermates were fed on an HFD. As the control, PFKFB3+/– mice and wild-type 
littermates were fed an LFD. Following the diet feeding for a period of 12 weeks, 
PFKFB3+/– mice weighed only slightly lesser than wild-type littermates on an LFD. 
However, on an HFD, PFKFB3+/– mice exhibited a much smaller gain in body weight 
than did wild-type littermates (Fig. 11). 
 
Disruption of PFKFB3/iPFK2 Blunts HFD-induced Adiposity 
            HFD-fed PFKFB3+/– mice exhibited a much smaller gain in body weight than did 
wild-type littermates. This was attributed, at least in part, to a smaller increase in visceral 
fat content (Fig. 12 A and B). Consistently, the adipocytes in PFKFB3+/– mice were 
markedly less enlarged than in wild-type littermates in response to HFD feeding as 
determined by histology (Fig. 12 C). To determine the possible contribution of food 
intake to the difference in body weight and adiposity, food intake of the mice was also 
monitored. However, there was no difference in food intake (data no shown). 
 
Disruption of PFKFB3/iPFK2 Alters Adipose Tissue Lipolysis 
Feeding an HFD to mice leads to adipose tissue dysfunction. To determine the 
effect of PFKFB3/iPFK2 disruption on HFD-induced adipose tissue dysfunction,  
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Figure 10. Changes of PFKFB3 mRNA and iPFK2 Amount and Activity in 
PFKFB3+/– Mice. A, The levels of PFKFB3 mRNA in epididymal adipose tissue were 
quantified using real-time RT-PCR. B, The amount of iPFK2 in both epididymal adipose tissue 
and brown adipose tissue was measured using Western blot. C, The levels of iPFK2 was 
quantified. D, The levels of F26P2 in epididymal adipose tissue were determined using the 
6PFK1 activation method. For A, C and D, data are means ± SE, n = 2 – 6. ** P < 0.01 and *** 
P < 0.001 PFKFB3+/– vs. wild-type; † †P < 0.01 wild-type EpiWAT vs. wild-type BAT. 
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Figure 11. Disruption of PFKFB3/iPFK2 Blunts HFD-induced Weight Gain. At the 
age of 5 – 6 weeks, PFKFB3+/– mice and wild-type littermates were fed a HFD or LFD 
for 12 weeks. Data are means ± SE, n = 6. * P < 0.05 and ** P < 0.01 HFD-PFKFB3+/– 
vs. HFD-wild-type; † P < 0.05 LFD-PFKFB3+/– vs. LFD-wild-type. 
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Figure 12. Disruption of PFKFB3/iPFK2 Blunts HFD-induced Adiposity. At the age 
of 5 – 6 weeks, PFKFB3+/– mice and wild-type littermates were fed a HFD or LFD for 
12 weeks. A and B, Changes in visceral fat content. The sum of epididymal, mesenteric, 
and perinephric fat mass was estimated as visceral fat content. C, Adipose tissue 
histology. The sections of epididymal fat pad were stained with H&E. For A and B, data 
are means ± SE, n = 6. * P < 0.05 and ** P < 0.01 HFD-PFKFB3+/– vs. HFD-wild-type. 
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Figure 13. Disruption of PFKFB3/iPFK2 Alters Adipose Tissue Lipolysis. At the age 
of 5 – 6 weeks, PFKFB3+/– mice and wild-type littermates were fed a HFD for 12 weeks. 
The rates of adipose tissue lipolysis were measured under both basal and isoproterenol-
stimulated conditions. Data are means ± SE, n = 6. * P < 0.05 and ** P < 0.01 HFD-
PFKFB3+/– vs. HFD-wild-type. 
 
 
 
 
changes in adipose tissue lipolysis was analyzed. Compared to those in HFD-fed wild-
type littermates, the rates of adipose tissue lipolysis were significantly higher in HFD-
fed PFKFB3+/– mice under both basal and isoproterenol-stimulated conditions (Fig. 13). 
 
Disruption of PFKFB3/iPFK2 Alters Adipokine Expression 
            To determine the effect of PFKFB3/iPFK2 disruption on HFD-induced adipose 
tissue dysfunction, changes in adipokine expression was analyzed. The mRNA levels of 
resistin were increased and the mRNA levels of adiponectin were decreased in the 
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adipose tissue in HFD-fed PFKFB3+/– mice compared to their respective levels in HFD-
fed wild-type littermates (Fig. 14).  
 
The Effects of Disruption of PFKFB3/iPFK2 on Macrophage Infiltration 
            Feeding an HFD to mice induces adipose tissue inflammation, which is 
characterized by macrophage infiltration and increased proinflammatory cytokine 
expression [125, 126]. The effects of disruption of PFKFB3/iPFK2 on macrophage 
infiltration were measured.  Compared to LFD-fed mice, HFD-fed PFKFB3+/– mice and 
wild-type littermates both revealed macrophage infiltration into the adipose tissue (data 
of LFD-fed mice not shown). However, PFKFB3+/– mice exhibited a smaller increase in 
HFD-induced macrophage infiltration in the adipose tissue compared to wild-type 
littermates (Fig. 15 A and B). Additionally, HFD feeding did not increase adipose tissue 
mRNA levels of F4/80 in PFKFB3+/– mice as did in wild-type mice (Fig. 15 C), which is 
consistent with changes in macrophage infiltration in the adipose tissue. 
 
Disruption of PFKFB3/iPFK2 Exacerbates HFD-induced Adipose Tissue 
Inflammatory Response 
            Feeding an HFD to mice induces adipose tissue inflammation, which is 
characterized by macrophage infiltration and increased proinflammatory cytokine 
expression [125, 126]. PFKFB3+/– mice exhibited a smaller increase in macrophage 
infiltration compared to HFD-fed wild-type mice. However, the mRNA levels of TNFα 
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Figure 14. Disruption of PFKFB3/iPFK2 Alters Adipokine Expression. At the age of 
5 – 6 weeks, PFKFB3+/– mice and wild-type littermates were fed a HFD for 12 weeks. 
The mRNA levels of adipose tissue resistin and adiponectin were measured. Data are 
means ± SE, n = 6. * P < 0.05 and ** P < 0.01 HFD-PFKFB3+/– vs. HFD-wild-type. 
 
 
 
 
 
 
 40 
 
 
 
 
Figure 15. The Effects of Disruption of PFKFB3/iPFK2 on Macrophage 
Infiltration. At the age of 5 – 6 weeks, PFKFB3+/– mice and wild-type littermates were 
fed a HFD for 12 weeks. A, Macrophage infiltration in adipose tissue. The sections of 
epididymal fat pad were immunostained for F4/80. B, Fraction of adipose tissue 
macrophages. C, The mRNA levels of adipose tissue F4/80. Data are means ± SE, n = 4 
– 6. * P < 0.05 and ** P < 0.01 HFD-PFKFB3+/– vs. HFD-wild-type  or PFKFB3+/– vs. 
wild-type on the same diet; † P < 0.05 and †† P < 0.01 HFD vs. LFD for the same 
genotype. 
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and IL-6 in adipose tissue were higher in HFD-fed PFKFB3+/– mice than in HFD-fed 
wild-type littermates (Fig. 16 A). Furthermore, similar trends were also observed in the 
mRNA levels of TNFα and IL-6 in macrophages and adipocytes isolated from the 
adipose tissue (Fig. 16 B and C). These data suggest that disruption of PFKFB3/iPFK2 
increases HFD-induced adipose tissue inflammatory response although it causes less 
macrophage infiltration. 
 
Disruption of PFKFB3/iPFK2 Increases Adipose Expression of Genes Involved in 
Fatty Acid Oxidation 
            To explore the role played by PFKFB3/iPFK2 in linking nutrient metabolism and 
the inflammatory response, the adipose tissue of HFD-fed mice was used for microarray 
analyses. Compared to wild-type littermates, PFKFB3+/– mice exhibited changes in the 
expression of 495 genes from a total of 23694 genes (P < 0.01). Of interest, PFKFB3+/– 
mice showed an increase in the expression of PPARα and PGC1, two master regulators 
that stimulate fatty acid oxidation [145-148], as well as an increase in the expression of 
oxidative-stress responsive 1 (Table 1). Using real-time RT-PCR, the increase in the 
mRNA levels of PPARα and PGC1 was confirmed (Fig. 17). Furthermore, the mRNA 
levels of CPT1, a key enzyme that controls the rate-limiting step of fatty acid oxidation 
[149, 150], was markedly increased in PFKFB3+/– mice (Fig. 17). These data suggest 
that PFKFB3/iPFK2 controls the status of adipocyte oxidative stress by regulating the 
balance between glycolysis and fatty acid oxidation.   
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Figure 16. Disruption of PFKFB3/iPFK2 Exacerbates HFD-induced Adipose Tissue 
Inflammatory Response. At the age of 5 – 6 weeks, PFKFB3+/– mice and wild-type 
littermates were fed a HFD for 12 weeks. The mRNA levels of inflammatory markers 
were quantified using real-time RT-PCR. A-C, The mRNA levels of TNFα and IL-6 in 
adipose tissue (A), as well as in macrophages (B) and adipocytes (C) isolated from 
adipose tissue. Data are means ± SE, n = 4 – 6. * P < 0.05 and ** P < 0.01 HFD-
PFKFB3+/– vs. HFD-wild-type. 
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Table 1. Selected adipose genes that are altered by disruption of PFKFB3/iPFK2 
 
Gene 
symbol   Gene name                           
Fold of 
change 
Gcgr Glucagon receptor 2.56 * 
Retn Resistin 2.15 * 
Ppara Peroxisome proliferator activated receptor alpha 1.68 * 
Ptprb Protein tyrosine phosphatase, receptor type, B 1.63 * 
Ppargc1a Peroxisome proliferative activated receptor, gamma, coactivator 1 alpha  1.56 * 
Rbp4 Retinol binding protein 4 1.54 * 
Ptprm Protein tyrosine phosphatase, receptor type, M 1.52 * 
 Oxidative-stress responsive 1 1.24 * 
Tnfrsf1b Tumor necrosis factor receptor superfamily, member 1b 0.67 * 
Stat3 Signal transducer and activator of transcription 3 0.66 * 
Il1rn Interleukin 1 receptor antagonist 0.65 * 
Srxn1 Sulfiredoxin 1 homolog (Saccharomyces. cerevisiae) 0.64 * 
Tnfrsf11a Tumor necrosis factor receptor superfamily, member 11a 0.60 * 
Acsl4 Acyl-CoA synthetase long-chain family member 4 0.60 * 
Timp1 Tissue inhibitor of metalloproteinase 1 0.44 * 
 
Adipose mRNA transcriptome was analyzed in HFD-fed PFKFB3+/– mice and wild-type 
littermates using microarray approach. Changes in the mRNA levels of adipose genes 
were expressed as the PFKFB3+/–/wild-type ratios. n = 4. * P < 0.05 PFKFB3+/– vs. wild-
type. 
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Figure 17. Disruption of PFKFB3/iPFK2 increases adipose expression of genes 
involved in fatty acid oxidation. At the age of 5 – 6 weeks, PFKFB3+/– mice and wild-
type littermates were fed a HFD for 12 weeks. The mRNA levels of genes involved in 
fatty acid oxidation in adipose tissue were quantified using real-time RT-PCR. Data are 
means ± SE, n = 4 – 6. * P < 0.05 and ** P < 0.01 HFD-PFKFB3+/– vs. HFD-wild-type. 
 
 
 
 
Disruption of PFKFB3/iPFK2 Decreases Adipose Tissue Insulin Signaling 
            To determine the effect of PFKFB3/iPFK2 disruption on HFD-induced adipose 
tissue dysfunction, changes adipose tissue insulin signaling were analyzed. Compared to 
HFD-fed wild-type mice, HFD-fed PFKFB3+/– mice exhibited a marked decrease in 
insulin-stimulated Akt phosphorylation (Fig. 18 A and B), indicating exacerbation of 
adipose tissue insulin resistance.  
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Figure 18. Disruption of PFKFB3/iPFK2 changes adipose tissue insulin signaling. 
At the age of 5 – 6 weeks, PFKFB3+/– mice and wild-type littermates were fed a HFD for 
12 weeks. . After anesthesia by an intraperitoneal (i.p.) injection of pentobarbital (50 
mg/kg body weight), mice were injected with insulin (1 U/kg) or PBS into the inferior 
vena cava (i.v.) and epididymal adipose tissue samples were collected 5 min later. A, 
Adipose tissue insulin signaling was determined by using western blot. B. The P-Akt and 
Akt levels were quantified.  
 
 
 
Disruption of PFKFB3/iPFK2 Exacerbates HFD-induced Systemic Insulin 
Resistance 
            Disruption of PFKFB3/iPFK2 changed adipose tissue lipolysis and adipokine 
expression, increased adipose tissue inflammatory response, and impaired adipose tissue 
insulin signaling, suggesting that disruption of PFKFB3/iPFK2 increases the severity of 
HFD-induced adipose tissue dysfunction. Adipose tissue dysfunction can contribute to 
the development of systemic insulin resistance [151, 152]. To determine changes in 
systemic insulin sensitivity, insulin and glucose tolerance tests were conducted. On a 
HFD, insulin resistance and glucose intolerance were more severe in PFKFB3+/– mice 
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than in wild-type littermates (Fig. 19 A and B), which were correlated with adipose 
tissue dysfunction well. Additionally, the levels of plasma glucose were significantly 
higher in PFKFB3+/– mice than in wild-type littermates on both an LFD and HFD (Table 
2). Consistent with changes in adiposity, the levels of plasma leptin were lower in 
PFKFB3+/– mice than in wild-type littermates on an HFD (Table 2). This may also 
contribute to exacerbation of insulin resistance in PFKFB3+/– mice.   
 
 
 
 
Figure 19. Disruption of PFKFB3/iPFK2 exacerbates HFD-induced systemic insulin 
resistance. At the age of 5 – 6 weeks, PFKFB3+/– mice and wild-type littermates were 
fed a HFD for 12 weeks. For A and B, mice were fasted for 4 h and received an i.p. 
injection of insulin (1 U/kg) (A) or D-glucose (2 g/kg) (B). Data are means ± SE, n = 6. 
* P < 0.05 and ** P < 0.01 HFD-PFKFB3+/– vs. HFD-wild-type. 
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Selective PFKFB3/iPFK2 Overexpression in Adipose Tissue 
            To address a direct role for the PFKFB3/iPFK2 in adipocytes, Tg mice was 
generated for analyzing aspects of diet-induced inflammatory and metabolic responses 
(Fig. 20 A and B). In confirmatory experiments, PFKFB3/iPFK2 overexpression was 
targeted to adipose tissue, but not in liver, muscle, or bone marrow (Fig. 20 C). Thus, Tg  
 
 
 
Table 2. Changes in the levels of plasma metabolites and insulin 
 
 
Serum Factor Wild-type PFKFB3+/– 
Glucose (mg/dl)   
         LFD              156 ± 16          202 ± 11 *  
         HFD  238 ± 6 ††          308 ± 8 **†† 
Insulin (ng/ml)   
         LFD  2.1 ± 0.3           3.2 ± 1.3 
         HFD       5.3 ± 1.6 †           8.1 ± 0.8 *†† 
Leptin (ng/ml)   
         LFD  4.2 ± 1.3           2.0 ± 0.7 
         HFD      65.0 ± 6.6 ††         43.8 ± 3.7 *†† 
Free fatty acids (mM)   
         LFD               0.1 ± 0           0.2 ± 0 * 
         HFD     0.2 ± 0.1 †           0.3 ± 0 † 
Triglycerides (mg/dl)    
         LFD                34 ± 1            40 ± 3 * 
         HFD                48 ± 4 †            51 ± 2 † 
 
At the age of 5 – 6 weeks, PFKFB3+/– mice and wild-type littermates were fed a HFD or 
LFD for 12 weeks. After the feeding regimen, mice were fasted for 4 h before collection 
of plasma samples. Data are means ± SE, n = 6.  * P < 0.05 and ** P < 0.01 PFKFB3+/– 
vs. wild-type on the same diet; † P < 0.05 and †† P < 0.01 HFD vs. LFD for the same 
genotype.  
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Figure 20. The generation of PFKFB3/iPFK2 adipocyte-specific overexpression 
mice. A. PCR analyses of mouse genomic DNA using an exon 2-specific primer with a 
neomycin-specific primer (+/–, heterozygous) or an exon 3-specific primer (+/+, wild-
type). B, genomic DNA was prepared from Adi-PFKFB3TG (Tg) mice and wild-type 
littermates and used for PCR analyses of aP2-PFKFB3 transgene. C. iPFK2 (encoded by 
PFKFB3) abundance in white adipose tissue (WAT), liver, skeletal muscle, and bone 
marrow (BM) was measured using Western blots. D, The levels of F26P2 in epididymal 
adipose tissue were determined using the 6PFK1 activation method. For D, data are means ± SE, 
n = 2 – 6. * P < 0.05 PFKFB3+/– vs. wild-type. 
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mice used here in overexpressed PFKFB3 selectively in adipose tissue. Because 
PFKFB3/iPFK2 determines the production of F26P2, the levels of adipose tissue F26P2 
were quantified as a direct indicator of iPFK2 activity. In Tg mice, the levels of adipose 
tissue F26P2 were significantly higher than those in wild-type littermates (Fig. 20 D). 
 
Adipocyte-specific PFKFB3/iPFK2 Overexpression Increases Body Weight and 
Adiposity 
            To determine the effect of PFKFB3/iPFK2 overexpression on diet-induced 
obesity, Tg mice and wild-type littermates were started on an HFD. As the control, Tg 
mice and wild-type littermates were fed an LFD. Following the diet feeding for a period 
of 12 weeks, the weight and fat mass of Tg mice are slightly higher than wild-type 
littermates on an LFD and an HFD (Fig. 21 A and B). 
 
Adipocyte-specific PFKFB3/iPFK2 Overexpression Protects Against Overnutrition-
induced Insulin Resistance and Glucose Intolerance 
            Although the weight and fat mass of Tg mice are slightly higher than wild-type 
littermates on an HFD, Tg mice displayed a much smaller increase in the severity of 
HFD induced systemic insulin resistance and glucose intolerance (Fig. 22 A and B). 
Therefore, selective overexpression of PFKFB3/iPFK2 in adipose tissue protects mice 
from diet-induced systemic insulin resistance and metabolic dysregulation. 
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Figure 21. Adipocyte-specific PFKFB3/iPFK2 overexpression increases body 
weight and adiposity. At the age of 5 – 6 weeks, Tg mice and wild-type littermates 
were fed a HFD or LFD for 12 weeks. A and B, Changes in weight and fat mass. For A 
and B, data are means ± SE, n = 6. ** P < 0.01 HFD vs. LFD for the same genotype. † P 
< 0.05 and †† P < 0.01 wild type mice vs. Tg mice. 
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Figure 22. Adipocyte-specific PFKFB3/iPFK2 overexpression protects against 
overnutrition-induced insulin resistance and glucose intolerance. A, insulin tolerance 
tests. B, glucose tolerance tests. A and B, male Tg mice and WT mice, at 5–6 weeks of 
age, were fed an HFD for 12 weeks. After the feeding regimen, HFD-fed mice were 
fasted for 4 h and received an intraperitoneal injection of insulin (1 unit/kg) (A) or 
glucose (2 g/kg) (B). Data are means ± S.E., n = 6–10. †, p < 0.05; ††, p < 0.01 Tg vs. 
WT at the same time point. 
 
 
 
Adipocyte-specific PFKFB3/iPFK2 Overexpression Suppresses Overnutrition-
induced Adipose Tissue Inflammatory Response and Improve Insulin Sensitivity 
            Feeding an HFD to mice induces adipose tissue inflammation, which is 
characterized by macrophage infiltration and increased proinflammatory cytokine 
expression [125, 126]. This is considered to be critical factors contributing to systemic 
insulin resistance. Compared with controls, adipose tissue of HFD-fed Tg mice 
accumulated more macrophages (Fig. 23, A and B) but showed a significant decrease in 
NF-κB p65 (Ser-468) phosphorylation (Fig. 23 C and D), indicating a decrease in 
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adipose tissue inflammatory response. In parallel, adipose tissue expression of 
proinflammatory cytokines TNFα and IL-6 was decreased (Fig. 23 E). When insulin 
signaling was analyzed, insulin-stimulated Akt (Ser-473) phosphorylation was increased 
in adipose tissue of Tg mice compared with WTmice (Fig. 23 F). Together, these results 
suggest that overexpression of PFKFB3/iPFK2 in adipose tissue suppresses diet-induced 
adipose tissue inflammatory response and insulin resistance while promoting fat 
deposition in adipose tissue. 
 
RESULTS OF CELL CULTURE STUDIES 
 
Knockdown of PFKFB3/iPFK2 Decreases Adipocyte Lipid Accumulation by 
Suppressing the Conversion of Glucose into Lipid 
            The direct role of PFKFB3/iPFK2 in regulating adipocyte metabolic and 
inflammatory responses was explored in 3T3-L1 adipocytes that were treated with 
shRNA against PFKFB3. As expected, knockdown of PFKFB3/iPFK2 was evidenced by 
a decrease in iPFK2 amount (Fig. 24 A and B). This resulted in a decrease in the 
adipocyte lipid accumulation compared to iPFK2-Ctrl adipocytes (Fig. 24 C) by 
suppressing the incorporation of glucose into lipid (Fig. 24 D). This results indicate that 
knockdown of PFKFB3/iPFK2 decreases glycolysis and glycolysis-derived lipogenesis 
and triglyceride synthesis. 
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Figure 23. Adipocyte-specific PFKFB3/iPFK2 overexpression suppresses 
overnutrition-induced adipose tissue inflammatory response and increase insulin 
sensitivity. At 5–6 weeks of age, male Tg and WT mice were fed an HFD for 12 weeks.  
A, macrophage infiltration in adipose tissue. The sections of epididymal fat pad were 
immunostained for F4/80. B. fraction of adipose tissue macrophages. C and D, adipose 
tissue inflammatory signaling. The levels of NF-κB p65 and phospho-p65 (Ser-468) 
were examined using Western blot analyses. E, TNFα and IL-6 expression were 
quantified using real time RT-PCR. F, adipose tissue insulin signaling. Tissue samples of 
HFD-fed mice were collected at 5 min after a bolus injection of insulin (1 unit/kg) or 
PBS into the portal vein. The levels of Akt1/2 and phospho-Akt (Ser-473) were 
examined using Western blot analyses. B, D and E data are means ± S.E., n = 6–10. †, p 
< 0.05; ††, p < 0.01 Tg vs. WT (B and E); **, p < 0.01 Tg vs. WT (D). 
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Figure 24. . Knockdown of PFKFB3/iPFK2 decreases adipocyte lipid accumulation 
by suppressing the conversion of glucose into lipid. Predifferentiated 3T3-L1 cells 
were transfected with the plasmid containing shRNA against PFKFB3/iPFK2 (iPFK2-
KD) or shRNA vector (iPFK2-Ctrl) for 24 h and induced for differentiation for 6 – 8 d. 
Un-transfected cells were differentiated similarly and used as the un-treated control. 
Some transfected 3T3-L1 cells were selected by puromycin (5 μg/ml) to establish stable 
iPFK2-KD or iPFK2-Ctrl cell lines. A, Western blot for iPFK2. B, The levels of iPFK2 
were quantified. Data are means ± SE, n = 2.  * P < 0.05 iPFK2-Ctrl vs. iPFK2-KD; † P 
< 0.05 Un-treated vs. iPFK2-KD. C, Changes in adipocyte lipid accumulation (arbitrary 
unit). D, Changes in the rates of glucose incorporation into lipid. Data are means ± S.E. n = 
4. ** P < 0.01 iPFK2-KD vs. iPFK2-Ctrl. 
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PFKFB3/iPFK2 Knockdown Exacerbates Adipocyte Inflammatory Response  
            Changes in the levels and phosphorylation states of JNK and NFκB p65 were 
determined in PFKFB3/iPFK2 knockdown and control adipocytes. Compared to iPFK2-
Ctrl adipocytes, iPFK2-KD adipocytes showed an increase in the phosphorylation states 
of JNK and NFκB p65 under both basal and LPS-stimulated conditions (Fig. 25 A, B 
and C). Additionally, the mRNA levels of TNFα and IL-6 were higher in iPFK2-KD 
adipocytes than in iPFK2-Ctrl adipocytes (Fig. 25 D). In combination, these data 
indicated that the inflammatory response in iPFK2-KD adipocytes was increased 
compared to iPFK2-Ctrl adipocytes, although knockdown of PFKFB3/iPFK2 reduced 
lipid accumulation.  
 
Reactive Oxygen Species (ROS) Generated by Excessive Fatty Acid Oxidation 
Triggers Adipocyte Inflammatory Response 
            Since the in vivo data suggested a potential role for PFKFB3/iPFK2 in linking 
fuel metabolism and oxidative stress, the production of ROS in cultured 3T3-L1 cells 
was determined to further illustrate the underlying mechanisms. Compared to iPFK2-
Ctrl adipocytes, iPFK2-KD adipocytes produced much more ROS under both basal and 
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Figure 25. PFKFB3/iPFK2 knockdown exacerbates adipocyte inflammatory 
response. Predifferentiated 3T3-L1 cells were transfected with the plasmid containing 
shRNA against PFKFB3/iPFK2 (iPFK2-KD) or shRNA vector (iPFK2-Ctrl) for 24 h and 
induced for differentiation for 6 – 8 d. Un-transfected cells were differentiated similarly 
and used as the un-treated control. Some transfected 3T3-L1 cells were selected by 
puromycin (5 μg/ml) to establish stable iPFK2-KD or iPFK2-Ctrl cell lines. A, 
Adipocytes were incubated with or without LPS (100 ng/ml) for 1 h prior to harvest. The 
levels and phosphorylation states of JNK and NFκB p65 were determined using Western 
blots. B and C, Phosphorylation states of JNK and NFκB p65 were quantified. D, mRNA 
levels of proinflammatory cytokines were quantified using real-time RT-PCR. Data are 
means ± S.E. n = 4. ** P < 0.01 iPFK2-KD vs. iPFK2-Ctrl 
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palmitate-stimulated conditions (Fig. 26 A), indicating an increase in the status of 
oxidative stress. To determine the contribution of elevated fatty acid oxidation to the 
increased production of ROS, the effect of etomoxir on ROS production was examined 
in the stable iPFK2-KD and iPFK2-Ctrl adipocytes. Treatment with etomoxir lowered 
down the production of ROS in palmitate-stimulated iPFK2-KD adipocytes to the level 
comparable with those brought about by treatment with N-acetyl-L-cysteine (Nac), a 
compound that inhibits most general pathways for ROS production (Fig. 26 B). These 
data suggest that elevated fatty acid oxidation is the major cause of the increased 
production of ROS when PFKFB3/iPFK2 is disrupted. Oxidative stress, which was 
formed by excessive ROS, plays a role in triggering inflammatory signaling through 
JNK and/or NFαB pathways [153, 154].  
 
PFKFB3/iPFK2 Knockdown Induces Adipocyte Dysfunction 
            Oxidative stress was identified for impairing insulin signaling [153, 154], 
therefore adipocyte function was determined. The metabolic changes in iPFK2-KD 
adipocytes were accompanied by an increase in the mRNA levels of resistin and a 
decrease in the mRNA levels of adiponectin, as well as a decrease in insulin-stimulated 
phosphorylation of Akt (Fig. 27 A, B and C), indicating impaired adipocyte function.  
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Figure 26. ROS generated by excessive fatty acid oxidation triggers adipocyte 
inflammatory response. Predifferentiated 3T3-L1 cells were transfected with the 
plasmid containing shRNA against PFKFB3/iPFK2 (iPFK2-KD) or shRNA vector 
(iPFK2-Ctrl) for 24 h and induced for differentiation for 6 – 8 d. Un-transfected cells 
were differentiated similarly and used as the un-treated control. Some transfected 3T3-
L1 cells were selected by puromycin (5 μg/ml) to establish stable iPFK2-KD or iPFK2-
Ctrl cell lines. The production of ROS was measured using the NBT assay. A, After 
differentiation, iPFK2-KD and iPFK2-Ctrl adipocytes were treated with or without 
palmitate (250 μM) for 24 h. B, After differentiation, the stable cell lines were treated 
with or without palmitate (250 μM) for 24 h. In the last hour of treatment, 100 μM 
etomoxir (an inhibitor of carnitine palmitoyltransferase-1, CPT1) or 10 mM N-acetyl-L-
cysteine (an antioxidant) was added. Data are means ± S.E. n = 4. * P < 0.05 and ** P < 
0.01 iPFK2-KD vs. iPFK2-Ctrl for the treatment of palmitate or vehicle in A and 
palmitate or vehicle with or without etomoxir or Nac in B; † P < 0.05 and †† P < 0.01 
palmitate vs. vehicle in A and palmitate in the presence of etomoxir or Nac vs. palmitate 
alone in B under the same condition (iPFK2-KD or iPFK2-Ctrl). 
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Figure 27. PFKFB3/iPFK2 knockdown induces adipocyte dysfunction.  
Predifferentiated 3T3-L1 cells were transfected with the plasmid containing shRNA 
against PFKFB3/iPFK2 (iPFK2-KD) or shRNA vector (iPFK2-Ctrl) for 24 h and 
induced for differentiation for 6 – 8 d. Un-transfected cells were differentiated similarly 
and used as the un-treated control. Some transfected 3T3-L1 cells were selected by 
puromycin (5 μg/ml) to establish stable iPFK2-KD or iPFK2-Ctrl cell lines. A, Changes 
in the mRNA levels of adipokines were quantified using real-time RT-PCR. B, Adipocyte 
insulin signaling was analyzed using Western blot. Before harvest, the cells were incubated with 
or without insulin (100 nM) for 30 min. C, Phosphorylation of Akt  and Akt were quantified. 
Data are means ± S.E. n = 4. * P < 0.05 iPFK2-KD vs. iPFK2-Ctrl. 
 
 
 
PFKFB3/iPFK2 Overexpression Increases Fat Deposition 
            Stable adipocytes overexpressing PFKFB3/iPFK2 (iPFK2-OX) were established 
(Fig. 28 A). Compared with GFP expressing adipocytes (control), iPFK2-OX adipocytes 
exhibited an increase in rates of glucose incorporation into lipid (Fig. 28 B). The data 
shows that PFKFB3/iPFK2 overexpression increases fat deposition in adipocytes.  
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Figure  28. PFKFB3/iPFK2 overexpression increases fat deposition. Stable iPFK2-
OX adipocytes and GFP-expressing adipocytes were established and subjected to 
metabolic and inflammatory assays. Each of the assays was performed at least in 
quadruplicate. A, amounts of iPFK2 in cells lysates were examined using Western blot 
analyses. B, changes in the rates of glucose incorporation into lipid. ††, p < 0.01 iPFK2-
OX vs. GFP. 
 
 
 
 
PFKFB3/iPFK2 Overexpression Dissociates Adipocyte Inflammatory Response and 
Insulin Resistance from Fat Deposition 
            iPFK2-OX is used to verify if PFKFB3/iPFK2 plays a direct role for in 
dissociating the inflammatory response and insulin resistance linked to fat deposition. 
iPFK2-OX showed a decrease in the generation of reactive oxygen species (ROS) under 
both basal (BSA) and palmitoleate-stimulated conditions (Fig. 29 A), indicating 
decreased the status of oxidative stress. Additionally, iPFK2-OX adipocytes showed a 
decrease in NF-κB p65 (Ser-468) phosphorylation (Fig. 29 B), as well as IL-6 expression 
in both basal (PBS) and TNFα-stimulated conditions compared with controls (Fig. 29 C). 
When insulin signaling was analyzed, iPFK2-OX adipocytes showed an increase in Akt 
(Ser-473) phosphorylation at both basal and insulin-stimulated conditions compared with 
control adipocytes (Fig. 29 D). Thus, PFKFB3/iPFK2 has direct effects on decreasing 
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adipocyte inflammatory response and on improving insulin signaling while increasing 
fat deposition.  
 
 
 
 
Figure  29. PFKFB3/iPFK2 overexpression decreases adipocyte inflammatory 
response and improves insulin signaling while increasing fat deposition. Stable 
iPFK2-OX adipocytes and GFP-expressing adipocytes were established and subjected to 
metabolic and inflammatory assays. Each of the assays was performed at least in 
quadruplicate. A, production of ROS was measured using the nitro blue tetrazolium 
(NBT) assay. B, adipocyte inflammatory signaling. The levels of NF-κB p65 and 
phospho-p65 (Ser-468) were examined using Western blot analyses. C, adipocyte 
expression of IL-6. D, adipocyte insulin signaling. Prior to harvest, adipocytes were 
incubated with or without insulin (100 nM) for 30 min. Phospho-Akt (Ser-473) to 
Akt1/2 ratios were calculated using densitometry and expressed as fold changes. A-D, 
adipocytes were incubated with or without palmitate (250 μM) for 24 h (A, B and D) or 
TNFα (10 ng/ml) for 6 h (C). A and C, †, p < 0.05; ††, p < 0.01 iPFK2-OX vs. GFP 
under the same condition (A and C). *, p < 0.05; **, p < 0.01 TNFα vs. PBS. 
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DISCUSSION 
 
Feeding an HFD to mice induces adiposity, which is associated with adipose 
tissue dysfunction, a key contributor of systemic insulin resistance [151, 152]. This is the 
case in wild-type littermates. However, in PFKFB3+/– mice, although bringing about a 
much smaller increase in adiposity, feeding an HFD caused a much greater increase in 
the severity of HFD-induced adipose tissue dysfunction and systemic insulin resistance 
than in wild-type littermates. These changes were attributed, at least in part, to the 
increased adipose tissue inflammatory response, which was evidenced by higher levels 
of proinflammatory cytokines in both isolated adipose tissue macrophages and 
adipocytes in PFKFB3+/– mice. Consistently, in cultured adipocytes, knockdown of 
PFKFB3/iPFK2 caused a decrease in lipid accumulation and an increase in the status of 
oxidative stress, which were accompanied by enhanced inflammatory signaling, 
increased mRNA levels of TNFα and IL-6, and decreased insulin signaling.  
            As a result of selective PFKFB3/iPFK2 overexpression in adipose tissue, Tg 
mice exhibited a dissociation of fat deposition, the inflammatory response, and insulin 
resistance. Locally, adiposity in HFD-fed Tg mice was greater than in wild-type 
littermates, which is consistent with the role of PFKFB3/iPFK2 in promoting glycolysis 
and glycolysis-derived lipogenesis as indicated by the results from PFKFB3/iPFK2-
overexpressing adipocytes. However, while showing increased adiposity, HFD-fed Tg 
mice exhibited a decrease in adipose tissue NF-κB p65 (Ser-468) phosphorylation and 
proinflammatory cytokine expression while accumulating more macrophages. Because 
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aP2-PFKFB3 primarily elevated PFKFB3/iPFK2, it is postulated that PFKFB3/iPFK2 is 
capable of mediating a dissociation of fat deposition and the inflammatory response. In 
support of this finding, PFKFB3/iPFK2 overexpression in adipocytes increased fat 
accumulation but decreased adipocyte inflammatory response. In PFKFB3/iPFK2 
overexpressing adipocytes, adipocyte ROS production and the inflammatory response 
are reduced while increasing fat accumulation. By altering lipid composition, 
PFKFB3/iPFK2 may dissociate adipose tissue/adipocyte fat deposition and the 
inflammatory response. When the inflammatory response was decreased, insulin 
signaling through Akt was improved in both adipose tissue of Tg mice and in 
PFKFB3/iPFK2-overexpressing adipocytes. 
            Together, these data argue in favor of a novel and unique role for 
PFKFB3/iPFK2 in regulating HFD-induced adipose tissue dysfunction and systemic 
insulin resistance in a manner independent of adiposity.    
In summary, the present study demonstrates a novel and unique role for 
PFKFB3/iPFK2 in regulating adiposity and adipose tissue function, and thereby 
systemic insulin sensitivity. This role is manifested by the fact that disruption of 
PFKFB3/iPFK2 ameliorates HFD-induced adiposity, but exacerbates HFD-induced 
adipose tissue dysfunction, in particular, adipose tissue inflammatory response, which 
contributes to an increase in the severity of systemic insulin resistance. Additionally, 
adipocyte-specific PFKFB3 over-expression increased adiposity but suppressed 
overnutrition induced adipose tissue inflammatory response and improved insulin 
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sensitivity. Thus, PFKFB3/iPFK2 protects against HFD-induced inflammation and 
insulin resistance independent of adiposity.  
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CHAPTER IV 
THE ROLE OF PFKFB3/iPFK2 IN THE ANTI-DIABETIC EFFECT OF PPARγ 
ACTIVATION* 
 
INTRODUCTION 
 
            Peroxisome proliferator-activated receptorγ (PPAR γ) is a nuclear receptor whose 
activation by thiazolidinediones (TZDs) effectively improves systemic insulin sensitivity 
and lowers plasma glucose levels in both human patients and rodent models of type 2 
diabetes [76-82, 155]. Because TZDs are effective in liver- or muscle-specific PPARγ -
deficient mice [87, 88] but not in adipose tissue-deleted mice [89] and adipose-specific 
PPARγ-deficient mice [90], adipose tissue has been considered as the primary target site 
for the anti-diabetic effect of PPARγ activation [75, 91]. Further investigations have 
suggested two adipose tissue-based mechanisms to largely explain the anti-diabetic 
effect of PPARγ activation [45, 81]. In the first mechanism, PPARγ activation by TZDs 
appropriately alters the expression of adipocyte genes that are involved in lipogenesis 
and triglyceride synthesis to increase the capacity of fat storage in adipose tissue [58, 94-
96, 100]. This leads to reduction of the circulating levels of free fatty acids (FFA) and  
thereby reversal of FFA-induced insulin resistance. In the second mechanism, PPARγ 
___________   
* Reprinted with permission from Guo, X., Huo, Y., Xu, K., Li, H., Zhang, W., Wang, 
H., Zhang, J., Lange, A.J., Chen, Y.E., and Wu, C. Involvement of inducible 6-
phosphofructo-2-kinase in the anti-diabetic effect of rosiglitazone in mice. J Biol Chem, 
2010. 285: 23711-23720. Copyright 2010 by the American Society for Biochemistry and 
Molecular Biology. 
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activation by TZDs suppresses the adipose tissue inflammatory response [58, 97] and 
appropriately regulates adipokine expression [81, 98, 99]. This improves adipose tissue 
function, which in turn brings about the insulin-sensitizing effect [81]. However, the 
molecular link between the two mechanisms remains to be elucidated.  
            Many PPARγ target genes are changed to promote fat storage in adipose tissue 
[100-103] when PPARγ is activated. TZDs stimulate the expression of Glycerol Kinase 
(GyK), which increases triglyceride synthesis in adipocytes by providing glycerol 3-
phosphate as a key substrate [100]. The activation of PPARγ also stimulates the 
expression of the cyto-solic isoform of Phosphoenolpyruvate Carboxykinase (PEPCK) in 
adipocytes [101, 102]. This increases glyceroneogenesis and provides another way to 
synthesize triglycerides in adipocytes/adipose tissue [104, 105]. In response to TZDs, the 
expression of several proinflammatory genes is decreased in the adipose tissue in both 
rodents and human patients with type 2 diabetes [95, 108]. Further, PPARγ activation in 
both adipose tissue macrophages and adipocytes contributes to the suppression of the 
adipose tissue inflammatory response [97, 109]. Cureently, mediators that are involved 
in the effect of PPARγ activation on adipocyte inflammatory response are largely 
unknown. 
            PFKFB3/iPFK2 is a target gene of PPARγ [156] and is stimulated by TZDs 
[110]. The expression of PFKFB3/iPFK2 is at high levels in adipose tissue and at very 
low levels in the liver and skeletal muscle [110, 133]. PFKFB3/iPFK2 plays a pivotal 
role for in regulating adipose tissue function and systemic insulin sensitivity in our 
recent study. Mechanistically, PFKFB3/ iPFK2 protects against fatty acid oxidation-
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associated reactive oxygen species (ROS) production, thereby reducing inflammatory 
signaling through JNK1 and NF-κB pathways to suppress adipocyte inflammatory 
response. However, the extent to which PFKFB3/iPFK2 participates in the in vivo 
effects of PPARγ activation is not known. Using PFKFB3/iPFK2-disrupted mice, the 
present study found that PFKFB3/iPFK2 is involved in the anti-diabetic effect of PPARγ 
activation, likely by increasing the ability of adipose tissue to store fat and by 
suppressing adipose tissue inflammatory response. In addition, the mechanisms 
underlying the involvement of PFKFB3/iPFK2 in the effects of PPARγ activation are 
explored in cultured 3T3-L1 adipocytes. 
 
MATERIALS AND METHODS 
 
Animal Experiments  
            Because homozygous disruption of PFKFB3/iPFK2 is embryonic lethal [133], 
PFKFB3+/– mice were generated as described previously [133] and used for the present 
study. Considering that rosiglitazone lowers the levels of plasma glucose and improves 
systemic insulin sensitivity only in diabetic mice, male PFKFB3+/– and wildtype 
littermates (C57BL/6J background) were fed a high fat diet (HFD) prior to treatment 
with rosiglitazone. Feeding an HFD to PFKFB3+/– mice exacerbates systemic insulin 
resistance and adipose tissue inflammatory response. Briefly, all mice were maintained 
as previously described. At the age of 5–6 weeks, mice were fed an HFD (60% fat 
calories, 20% protein calories, and 20 carbohydrate calories) (Research Diets, Inc., New 
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Brunswick, NJ) for 12 weeks. During the last 4 weeks of the feeding regimen, HFD-fed 
mice were treated with rosiglitazone (10 mg/kg/day in PBS; Avandia tablets) or vehicle 
(PBS) via oral gavages. As the control, the age-matched male mice were fed a low fat 
diet (10% fat calories, 20% protein calories, and 70% carbohydrate calories) and 
received no treatment. The composition of both HFD and low fat diet has been described 
previously. Body weight and food intake of the mice were recorded every 4 days during 
the 12-week feeding period. At the end of the feeding/treatment regimen, mice were 
fasted for 4 h before sacrifice for collection of blood and tissue samples as described 
previously [135-137]. Visceral fat content was estimated as the sum of epididymal, 
mesenteric, and perinephric fat depots [136]. After weighing, lipolysis rates were 
determined on adipose tissue samples. Some tissue samples were either fixed and 
embedded for histological analyses or frozen in liquid nitrogen and then stored at - 80 °C 
for further analyses. Some mice were fasted similarly and used for glucose and insulin 
tolerance tests. For a separate study to analyze the role of PPARγ in regulating PFKFB3 
expression, PPARγ2 +/–  mice and their wild-type littermates were generated as described 
before [120] and used for adipose tissue sample collection and embryonic fibroblast 
isolation. All study protocols were reviewed and approved by the Institutional Animal 
Care and Use Committee of Texas A&M University. 
 
Measurement of Metabolite and Hormone Levels  
            The levels of plasma metabolites, such as glucose, triglycerides, and FFA, were 
measured using metabolic assay kits (Sigma and BioVision (Mountain View, CA)). The 
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levels of plasma hormones (i.e. insulin and leptin) were measured using enzyme-linked 
immunosorbent assay kits (Crystal Chem Inc., Downers Grove, IL). The levels of 
adipose tissue fructose 2,6-bisphosphate (F26P2) were determined using the 6-
phosphofructo-1-kinase activation method as described previously [137]. 
 
Glucose and Insulin Tolerance Tests  
            The assays were conducted as previously described [137]. After fasting for 4 h, 
mice received a peritoneal injection of D-glucose (2 g/kg) or insulin (0.5 unit/kg) 
(Humulin, Lily). 
 
Measurement of Adipose Tissue Lipolysis  
            The assays were conducted as described previously [138, 139]. Briefly, freshly 
isolated adipose tissue samples were washed several times with PBS and incubated in a 
final volume of 1 ml of high glucose 
Dulbecco’s modified Eagle’s medium containing 2% fatty acid free bovine serum 
albumin in the presence or absence of 10 μM isoproterenol at 37 °C for 3 h. Aliquots of 
the medium were sampled hourly to quantify glycerol content using metabolic kits 
(BioVision, Mountain View, CA). The rate of lipolysis was estimated as the efflux of 
glycerol. 
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Histological Analyses of Adipose Tissue  
            The paraffin-embedded adipose tissue blocks were cut into sections of 5-μm 
thickness and stained with hematoxylin and eosin. 
 
Cell Culture and Treatment  
          3T3-L1 cells were maintained in high glucose Dulbecco’s modified Eagle’s 
medium and differentiated in induction medium for 6–8 days as described previously. To 
explore the direct role of PFKFB3/iPFK2 in modulating the effect of PPARγ activation, 
stable PFKFB3/iPFK2-knockdown (iPFK2-KD) 3T3-L1 cells and control (iPFK2-Ctrl) 
3T3-L1 cells were used. These cells have been previously established. During the last 48 
h of differentiation, both iPFK2-KD and iPFK2-Ctrl adipocytes were treated with 
rosiglitazone (1μM) or vehicle (0.1% DMSO) and used to quantify the expression of 
PPARγ target genes as well as for further analyses using the methods described below. 
            To quantify adipocyte lipid content, the cells were stained with Oil Red O. The 
lipid-associated dye was extracted with isopropyl alcohol for 15 min. The OD of the 
extraction solution was measured using a spectrophotometer at 510 nm [120]. To 
determine the rate of glucose incorporation into lipid, each well (6-well plate) of the 
cells was incubated with Dulbecco’s modified Eagle’s medium supplemented with 1 μCi 
of [U-14C] glucose for 24 h as described previously [141]. After sequential extraction 
with 30% KOH, 95% ethanol, 9 M H2SO4, and petroleum ether, the amount of 
14C-
labeled lipids was quantified using a Beckman liquid scintillation counter. To analyze 
inflammatory signaling, the cells were incubated with palmitate (250 μM) or vehicle 
(0.5% bovine serum albumin) for 24 h. Cell lysates were then prepared and used for 
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Western blots to measure the levels and phosphorylation states of JNK and NF-κB p65. 
To determine adipocyte expression of proinflammatory cytokines and adipokines, the 
total RNA of the cells was prepared and used for real-time RT-PCR. To determine 
changes in insulin signaling, the cells were treated with or without insulin (100 nM) for 
30 min prior to harvest. Cell lysates were prepared and used to measure the levels and 
phosphorylation of Akt using Western blots. 
            PFKFB3/iPFK2-knockdown-associated increase in fatty acid oxidation triggers 
adipocyte inflammatory response, which may account for lessening or blunting of the 
anti-inflammatory effect of PPARγ activation. To verify this concept, the differentiated 
stable iPFK2-KD and iPFK2-Ctrl adipocytes were treated with rosiglitazone (1 μM) or 
vehicle (0.1% DMSO) for 48 h. In the last 24 h, 100 μM etomoxir (an inhibitor of 
carnitine palmitoyltransferase-1), with or without palmitate (250 μM), was added to 
rosiglitazone-treated cells. Thereafter, the cells were used to measure the production of 
ROS using the nitro blue tetrazolium assay as described previously [142] or harvested to 
analyze adipocyte inflammatory response and insulin signaling as described above. 
 
RNA Isolation, Reverse Transcription, and Real-time PCR  
            The total RNA was isolated from frozen tissue samples and cultured cells. RNA 
isolation and real-time RT-PCR were conducted as described previously [137]. The 
mRNA levels were analyzed for PFKFB3, GyK, PEPCK, PPARγ, resistin, adiponec 
adiponectin, tumor necrosis factor α (TNFα), and interleukin-6 (IL-6) in adipose tissue 
samples and/or cell samples. 
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Western Blots  
            Lysates were prepared from frozen tissue samples and cultured cells. Western 
blots were conducted as described previously [136, 137]. The levels of JNK, phospho-
JNK, NF-κB p65, phospho-p65, Akt1/2, and phospho-Akt (Ser473) were analyzed. 
 
Statistical Methods  
            Numeric data are presented as means ± S.E. Statistical significance was assessed 
by unpaired, two-tailed analysis of variance or Student’s t test. Differences were 
considered significant at the two-tailed p < 0.05. 
 
RESULTS 
 
Disruption of PFKFB3/iPFK2 Blunts the Anti-diabetic Effect of PPARγ Activation 
            After a feeding of an HFD, wild-type littermates exhibited insulin resistance, 
glucose intolerance, and hyperglycemia. In these wild-type mice, treatment with 
rosiglitazone for 4 weeks normalized the levels of plasma glucose (169.67 ± 6.05 versus 
242.59 ± 6.23 mg/dl, p < 0.01; Fig. 30 A) and corrected glucose intolerance and insulin 
resistance (Fig. 30, B and C) compared with vehicle. Additionally, treatment with 
rosiglitazone lowered the circulating levels of insulin (Fig. 30 D), indicating the reversal 
of hyperinsulinemia. These data confirmed the anti-diabetic effect of PPARγ activation. 
Consistent with our previous study, feeding an HFD to PFKFB3+/– mice exacerbated 
systemic insulin resistance and adipose tissue inflammatory response. In these  
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Figure  30. Disruption of PFKFB3/iPFK2 blunts the anti-diabetic effect of PPARγ 
activation. Male PFKFB3+/– mice and wild-type littermates, at the age of 5–6 weeks, 
were fed an HFD for 12 weeks and treated with rosiglitazone (10 mg/kg/day) or vehicle 
(PBS) during the last 4 weeks of HFD feeding. Data are means ± S.E. (error bars), n = 6. 
A, changes in the levels of plasma glucose. As the control, the age-matched male 
PFKFB3+/– mice and wild-type littermates were fed a low fat diet (LFD) and received no 
treatment. All of the mice were fasted for 4 h before collection of blood samples. **, p < 
0.01, rosiglitazone versus vehicle within the same genotype. †, p < 0.05; ††, p < 0.01, 
PFKFB3+/– vs. wild type on an HFD with the same treatment (rosiglitazone or vehicle). 
For B and C, mice were fasted for 4 h and received an intraperitoneal injection of D-
glucose (2 g/kg) (B) or insulin (0.5 units/kg) (C). *, p < 0.05; **, p < 0.01, wild 
type/rosiglitazone vs. wild type/vehicle. †, p < 0.05; ††, p < 0.01, PFKFB3+/–
/rosiglitazone vs. wild type/rosiglitazone. B, glucose tolerance test. C, insulin tolerance 
test. D, changes in the levels of plasma insulin. Mice were fed and/or treated as 
described in A. Statistical analyses were identical to those in A. 
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PFKFB3/iPFK2- disrupted mice, treatment with rosiglitazone only caused an 
insignificant decrease in the levels of plasma glucose (263.14 ±13.20 versus 297.05 ± 
12.30 mg/dl; Fig. 30 A) and failed to improve insulin resistance and glucose intolerance. 
Thus, disruption of PFKFB3/iPFK2 blunts the anti-diabetic effect of PPARγ activation. 
 
Disruption of PFKFB3/iPFK2 Impairs the Response of Adipose Tissue 
PFKFB3/iPFK2 to PPARγ Activation 
            TZDs primarily target adipose tissue [89, 90] and stimulate the expression of 
PFKFB3/iPFK2 in adipocytes [110]. To address the link between adipose tissue 
PFKFB3/iPFK2 and the anti-diabetic effect of PPARγ activation, the response of 
adipose tissue PFKFB3/iPFK2 to rosiglitazone was determined. Compared with vehicle, 
rosiglitazone treatment caused a significant increase in the mRNA levels of adipose 
PFKFB3/iPFK2 in wild-type littermates, confirming the stimulatory effect of PPARγ 
activation. However, this stimulatory effect was markedly lessened in PFKFB3+/– mice 
(Fig. 31, A and B). Because PFKFB3/iPFK2 determines the production of F26P2, the 
levels of adipose tissue F26P2 were quantified to reflect PFKFB3/iPFK2 activity. 
Consistent with an increase in the mRNA levels of PFKFB3/iPFK2, the levels of adipose 
tissue F26P2 were significantly higher in rosiglitazone-treated wild-type mice than in 
vehicle-treated wild-type mice (3.54 ± 0.48 versus 1.77 ± 0.21nmol/g, p < 0.05; Fig. 31 
C). However, in PFKFB3+/– mice, rosiglitazone only caused a slight and insignificant 
increase in the levels of F26P2 compared with vehicle (1.29 ± 0.29 versus 0.92 ± 0.08  
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Figure  31. Disruption of PFKFB3/iPFK2 impairs the response of adipose tissue 
PFKFB3/iPFK2 to PPARγ activation. At the age of 5– 6 weeks, male PFKFB3+/– mice 
and wild-type littermates were fed an HFD for 12 weeks and treated with rosiglitazone 
(10 mg/kg/day) or vehicle (PBS) during the last 4 weeks of HFD feeding. At the end of 
the feeding/treatment regimen, mice were fasted for 4 h before collection of tissue 
samples. Epididymal adipose tissue samples were used for the analyses. A, the mRNA 
levels of PFKFB3 were measured using real-time RT-PCR. B, adipose tissue iPFK2 was 
determined using Western blot. C, adipose tissue F26P2 levels were determined using 
the 6-phosphofructo-1-kinase activation method. For A and C, data are means ± S.E. 
(error bars), n=6. *, p < 0.05; **, p < 0.01, rosiglitazone vs. vehicle within the same 
genotype (in A and C). †, p < 0.05; ††, p < 0.01, PFKFB3+/– vs. wild type with the same 
treatment (rosiglitazone or vehicle in A and C). 
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nmol/g). These data suggest that two intact PFKFB3/iPFK2 alleles are necessary for 
mice to fully respond to PPARγ activation. 
 
Disruption of PFKFB3/iPFK2 Does not Impair the Response of Other PPARγ 
Target Genes to PPARγ Activation 
            To address whether disruption of PFKFB3/iPFK2 impairs the response of other 
PPARγ target genes to PPARγ activation, the expression of GyK and PEPCK as well as 
PPARγ in the adipose tissue was determined. Under the basal condition (treatment with 
vehicle), the expression of the GyK, PEPCK, and PPARγ in PFKFB3+/– mice did not 
differ from that in wild-type mice (Fig. 32, A and B). Furthermore, in response to 
PPARγ activation by rosiglitazone treatment, the expression of GyK and PEPCK in 
PFKFB3+/– mice was increased to an extent comparable with that in wild-type littermates 
(Fig. 32, A and B). These data indicate that PPARγ expression, PPARγ translocation to 
cell nuclei, and activation of PPARγ-targeted genes are not disturbed in PFKFB3+/– 
mice. 
 
Disruption of PFKFB3/iPFK2 Lessens the Effect of PPARγ Activation on 
Increasing Adipose Tissue Fat Storage 
            Increasing adipose tissue fat storage, to a large extent, accounts for the anti-
diabetic and insulin-sensitizing effects of PPARγ activation [95, 100, 103]. Changes in 
the rate of adipose tissue lipolysis, the content of visceral fat, and the size of epididymal 
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adipocytes were determined to address the extent to which PPARγ activation increases 
the ability of adipose tissue to store fat in the mice. In wild-type littermates, treatment 
 
Figure  32. Disruption of PFKFB3/iPFK2 does not impair the response of other 
PPARγ target genes to PPARγ activation. At the age of 5– 6 weeks, male PFKFB3+/– 
mice and wild-type littermates were fed an HFD for 12 weeks and treated with 
rosiglitazone (10 mg/kg/day) or vehicle (PBS) during the last 4 weeks of HFD feeding. 
At the end of the feeding/treatment regimen, mice were fasted for 4 h before collection 
of tissue samples. Epididymal adipose tissue samples were used for the analyses. A, 
representative PCR products of adipose tissue genes. B, quantification of the expression 
of adipose tissue genes. Rosi, rosiglitazone. For E, data are means ± S.E.(error bars), 
n=6. *, p < 0.05; **, p < 0.01, wild type/rosiglitazone vs. wild type/vehicle and 
PFKFB3+/–/rosiglitazone vs. PFKFB3+/–/vehicle for the same gene. 
 
 
 
 
with rosiglitazone caused a significant decrease in adipose tissue lipolysis and an 
increase in visceral fat content (Fig. 33, A and B). However, in PFKFB3+/– mice, 
treatment with rosiglitazone did not bring about significant changes in any of the above  
 78 
 
 
 
Figure  33. Disruption of PFKFB3/iPFK2 lessens the effect of PPARγ activation on 
increasing adipose tissue fat storage. At the age of 5–6 weeks, male PFKFB3+/–mice 
and wild-type littermates were fed anHFDfor 12 weeks and treated with rosiglitazone 
(10 mg/kg/day) or vehicle (PBS) during the last 4 weeks of HFD feeding. At the end of 
the feeding/treatment regimen, mice were fasted for 4 h before collection of tissue 
samples. For A and B, data are means ± S.E. (error bars), n = 6. *, p < 0.05 rosiglitazone 
vs. vehicle within the same genotype (in A and B) in the presence of the same condition 
(in A, basal or isoproterenol). †, p < 0.05; ††, p < 0.01, PFKFB3+/– vs. wild type with the 
same treatment (in A and B, rosiglitazone or vehicle) in the presence of the same 
condition (in A, basal or isoproterenol). A, the rates of adipose tissue lipolysis were 
measured under both basal and isoproterenol-stimulated conditions. B, visceral fat 
content was estimated from the sum of epididymal, mesenteric, and perinephric fat mass. 
C, adipose tissue histology. The sections of epididymal fat pad were stained with 
hematoxylin and eosin. 
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parameters. Additionally, the size of epididymal adipocytes was much larger in 
rosiglitazone-treated wild-type mice than in rosiglitazone-treated PFKFB3+/– mice (Fig. 
33 C). Together, these data demonstrate that disruption of PFKFB3/iPFK2 lessens the 
effect of PPARγ activation on increasing adipose tissue fat storage. 
 
Disruption of PFKFB3/iPFK2 Blunts the Effects of PPARγ Activation on 
Suppression of HFD-induced Adipose Tissue Inflammatory Response and on 
Reversal of Adipose Tissue Dysfunction 
            Suppression of adipose tissue inflammatory response is one of the major 
mechanisms by which PPARγ activation reverses insulin resistance and corrects 
hyperglycemia [81, 97, 157]. The effects of PPARγ activation on adipose tissue 
inflammatory signaling and proinflammatory cytokine expression were determined. In 
HFD-fed wild-type littermates, treatment with rosiglitazone brought about a decrease in 
the phosphorylation of JNK1 and NF-κB p65 (Fig. 34, A and B), which was 
accompanied by a significant decrease in the mRNA levels of TNFα and IL-6 compared 
with treatment with vehicle (Fig. 34 C). Because suppression of adipose tissue 
inflammatory response is linked to reversal of adipose tissue dysfunction [81, 158], 
adipose expression of adipokines and insulin signaling were analyzed. Compared with 
vehicle, treatment with rosiglitazone caused a decrease in adipose mRNA levels of 
resistin and an increase in adipose mRNA levels of adiponectin (Fig. 34 D) and an 
increase in insulin-stimulated phosphorylation of Akt (Fig. 34 E), all of which 
contributed to the effects of PPARγ activation on reversal of systemic insulin resistance 
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and on correction of hyperglycemia. However, in PFKFB3+/– mice, treatment with 
rosiglitazone did not effectively suppress adipose tissue inflammatory signaling and the 
mRNA levels of TNFα and IL-6 compared with treatment with vehicle (Fig. 34, A–C). 
Additionally, treatment with rosiglitazone did not appropriately alter adipose expression 
of resistin and adiponectin as it did in wild-type mice (Fig. 34 D) and failed to increase 
insulin-stimulated phosphorylation of Akt (Fig. 34 E). Collectively, these data 
demonstrate that disruption of PFKFB3/iPFK2 blunts the effects of PPARγ activation on 
suppressing HFD-induced adipose inflammatory response and on reversing adipose 
tissue dysfunction. 
 
Knockdown of PFKFB3/iPFK2 Lessens the Effect of PPARγ Activation on 
Stimulating Adipocyte Lipid Accumulation 
            The direct role of PFKFB3/iPFK2 in modulating the effect of PPARγ activation 
on lipid accumulation was explored in iPFK2-KD and iPFK2-Ctrl 3T3-L1 adipocytes. 
Compared with that in iPFK2-Ctrl cells, the amount of iPFK2 was low and was not 
increased by rosiglitazone treatment in iPFK2-KD adipocytes (Fig. 35 A). Under the 
basal condition (treatment with vehicle), iPFK2-KD adipocytes accumulated less lipid 
than did iPFK2- Ctrl adipocytes (Fig. 35, B and C), which was attributed to a decrease in 
the rate of glucose incorporation into lipid (Fig. 35 D). After treatment with 
rosiglitazone, iPFK2-KD adipocytes exhibited a much smaller increase in lipid 
accumulation and the rate of glucose incorporation into lipid than did iPFK2-Ctrl  
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Figure  34. Disruption of PFKFB3/iPFK2 blunts the effects of PPARγ activation on 
suppression of HFD induced adipose tissue inflammatory response and on reversal 
of adipose tissue dysfunction. At the age of 5–6 weeks, male PFKFB3+/– mice and 
wild-type littermates were fed an HFD for 12 weeks and treated with rosiglitazone (10 
mg/kg/day) or vehicle (PBS) during the last 4 weeks of HFD feeding. At the end of the 
feeding/treatment regimen, mice were fasted for 4 h before the collection of tissue 
samples. Rosi, rosiglitazone. A, changes in inflammatory signaling were analyzed using 
Western blots. B, quantification of inflammatory signaling (arbitrary units). C, changes 
in adipose mRNA levels of TNFα and IL-6. D, changes in adipose mRNA levels of 
resistin and adiponectin. For B and D, data are means ± S.E. (error bars), n = 6. *, p < 
0.05; **, p < 0.01, wild type/rosiglitazone versus wild type/vehicle for the same gene. †, 
p < 0.05; ††, p < 0.01 PFKFB3+/–/vehicle versus wild type/vehicle or PFKFB3+/–
/rosiglitazone versus wild type/rosiglitazone for the same gene. For C and D, the 
expression of adipose tissue genes was measured using real-time RT-PCR. E, adipose 
tissue insulin signaling was analyzed using Western blot. Adipose tissue samples were 
collected at 5 min after a bolus injection of insulin (1 unit/kg) into the portal vein. P-p54, 
phospho-p54; P-p46, phospho-p46; P-Akt, phospho-Akt. 
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adipocytes. This occurred where the response of GyK and PEPCK to PPARγ activation 
in iPFK2-KD adipocytes was comparable with that in iPFK2-Ctrl adipocytes (data not 
shown), indicating the importance of PFKFB3/iPFK2 to the effect of PPARγ activation 
on stimulating adipocyte lipid accumulation. These data, consistent with those observed 
in rosiglitazone- treated PFKFB3+/– mice, demonstrate that adipocyte PFKFB3/iPFK2 is 
needed, at least in part, for PPARγ activation to increase adipose tissue fat storage.  
 
Knockdown of PFKFB3/iPFK2 Diminishes the Effects of PPARγ Activation on 
Suppression of Adipocyte Inflammatory Response 
            The direct role of PFKFB3/iPFK2 in modulating the effects of PPARγ activation 
on adipocyte inflammatory response and on adipocyte function was explored. In iPFK2-
Ctrl adipocytes, treatment with rosiglitazone caused a significant decrease in palmitate-
stimulated phosphorylation of JNK1 and NF-κB p65 (Fig. 36, A and B), which was 
accompanied by a decrease in the mRNAlevels of TNFα and IL-6 (Fig. 36 C). In 
contrast, treatment of iPFK2-KD adipocytes with rosiglitazone did not effectively bring 
about a significant decrease in palmitate-stimulated phosphorylation of JNK1 and NF-
κB p65 and failed to suppress the mRNA levels of TNFα and IL-6 (Fig. 36, A–C). These 
data, along with those observed in rosiglitazone-treated PFKFB3+/– mice, suggest that 
the intact PFKFB3/iPFK2 in adipocytes is needed, at least in part, for PPARγ activation 
to suppress adipose tissue inflammatory response. 
 
 
 83 
 
 
 
Figure  35. Knockdown of PFKFB3/iPFK2 lessens the effect of PPARγ activation on 
stimulating adipocyte lipid accumulation. After differentiation for 6–8 days, stable 
iPFK2-KD and iPFK2-Ctrl adipocytes were treated with rosiglitazone (Rosi; 1 μM) or 
vehicle (0.1% DMSO) for 48 h. Thereafter, the treated cells were subjected to the assays 
described under “Experimental Procedures.” A, adipocyte iPFK2 was determined using 
Western blot. B, representative images of adipocyte lipid content. Yellow bar, 500 μm. 
For C and D, data are means ± S.E. (error bars), n = 4. **, p < 0.01, iPFK2-KD/vehicle 
or iPFK2-Ctrl/rosiglitazone vs. iPFK2-Ctrl/vehicle; ††, p < 0.01, iPFK2-KD/Rosi vs. 
iPFK2-Ctrl/rosiglitazone. C, quantification of adipocyte lipid accumulation (arbitrary 
units).D, changes in the rate of glucose incorporation into lipid. 
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Figure  36. Knockdown of PFKFB3/iPFK2 diminishes the effects of PPARγ 
activation on suppression of adipocyte inflammatory response. After differentiation 
for 6–8 days, stable iPFK2-KD and iPFK2-Ctrl adipocytes were treated with 
rosiglitazone (Rosi; 1 μM) or vehicle (0.1% DMSO) for 48 h in the presence or absence 
of palmitate (Pal; 250 μM) for the last 24 h. Thereafter, the treated cells were subjected 
to the assays described under “Experimental Procedures.” A, changes in inflammatory 
signaling were analyzed using Western blots. For B and C, data are means ± S.E., n = 4. 
B, quantification of inflammatory signaling (arbitrary units). Left, phospho-JNK1 (P-
JNK1)/JNK1; right, phospho-p65 (P-p65)/p65. **, p < 0.01, iPFK2-Ctrl treated with 
Rosi vs. iPFK2-Ctrl treated without Rosi in the presence or absence of Pal. ††, p < 0.01, 
iPFK2-KD vs. iPFK2-Ctrl under the same condition. For C, the expression of 
proinflammatory cytokines was measured using real-time RT-PCR. *, p < 0.05, iPFK2-
Ctrl/rosiglitazone versus iPFK2-Ctrl/vehicle for the same gene. ††, p < 0.01, iPFK2-
KD/vehicle vs. iPFK2-Ctrl/vehicle or iPFK2-KD/rosiglitazone vs. iPFK2-
Ctrl/rosiglitazone for the same gene.  
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Knockdown of PFKFB3/iPFK2 Diminishes the Effects of PPARγ Activation on 
Improvement of Adipocyte Function 
            Increased inflammatory response contributes to inappropriate expression of 
adipokines and decreased insulin signaling in adipocytes. To analyze the direct 
involvement of PFKFB3/iPFK2 in the effect of PPARγ activation on adipocyte function, 
the mRNA levels of resistin and adiponectin as well as insulin signaling were 
determined in rosiglitazone- or vehicle-treated iPFK2-KD and iPFK2-Ctrl adipocytes. 
Compared with vehicle, treatment with rosiglitazone caused a decrease in the mRNA 
levels of resistin and an increase in the mRNA levels of adiponectin in iPFK2-Ctrl 
adipocytes (Fig. 37 A). Additionally, treatment with rosiglitazone brought about an 
increase in insulin-stimulated phosphorylation of Akt in iPFK2-Ctrl adipocytes (Fig. 37 
B). However, these beneficial effects of rosiglitazone were diminished in iPFK2-KD 
adipocytes. Together, these data suggest that PFKFB3/iPFK2 is directly involved in the 
effect of PPARγ activation on improving adipocyte function. 
 
Inhibition of Fatty Acid Oxidation Restores the Effects of PPARγ Activation on 
Both Suppression of Adipocyte Inflammatory Response and Stimulation of 
Adipocyte Insulin Signaling 
            PFKFB3/iPFK2 links fuel metabolism and inflammatory response in adipocytes 
via suppression of fatty acid oxidation-associated production of ROS. The extent to 
whichPFKFB3/iPFK2modulates the effect of PPARγ activation on ROS production was 
determined. Compared with that in iPFK2-Ctrl adipocytes, the ROS production was 
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Figure  37. Knockdown of PFKFB3/iPFK2 diminishes the effects of PPARγ 
activation on improving of adipocyte function. After differentiation for 6–8 days, 
stable iPFK2-KD and iPFK2-Ctrl adipocytes were treated with rosiglitazone (Rosi; 1 
μM) or vehicle (0.1% DMSO) for 48 h in the presence or absence of palmitate (Pal; 250 
μM) for the last 24 h. Thereafter, the treated cells were subjected to the assays described 
under “Experimental Procedures.” A, the expression of adipokines was measured using 
real-time RT-PCR. *, p < 0.05, iPFK2-Ctrl/rosiglitazone versus iPFK2-Ctrl/vehicle for 
the same gene. ††, p < 0.01, iPFK2-KD/vehicle vs. iPFK2-Ctrl/vehicle or iPFK2-
KD/rosiglitazone vs. iPFK2-Ctrl/rosiglitazone for the same gene. B, adipocyte insulin 
signaling was analyzed using Western blot. Before harvest, the cells were incubated with 
or without insulin (100 nM) for 30 min. P-p46, phospho-p46. 
 
 
 
higher in iPFK2-KD adipocytes under the basal condition (without palmitate) and was 
markedly increased in the palmitate-stimulated condition (Fig. 38 A). Upon treatment 
with rosiglitazone, the ROS production was low in iPFK2-Ctrl adipocytes and remained 
unchanged upon the addition of palmitate. However, in iPFK2-KD adipocytes, 
rosiglitazone treatment did not significantly decrease the basal ROS production and 
failed to blunt the palmitate-induced increase in ROS production (Fig. 38 A). It appears 
that PFKFB3/iPFK2-knockdown-associated increase in ROS production blunts the 
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beneficial effects of PPARγ activation in iPFK2-KD adipocytes. Next, we determined 
the extent to which correction of excessive ROS production restores the effects of 
PPARγ activation on inflammatory response and insulin signaling in iPFK2-KD 
adipocytes. Upon inhibition of fatty acid oxidation by etomoxir, palmitate-stimulated 
ROS production in iPFK2-KD adipocytes was decreased to a level comparable with that 
in untreated iPFK2-Ctrl adipocytes (Fig. 38 B). Under this condition, treatment with 
rosiglitazone brought about a decrease in the phosphorylation of JNK1 and NF-κB p65 
as well as the mRNA levels of TNFα and IL6 in iPFK2-KD adipocytes to their 
respective levels comparable with those in rosiglitazone-treated iPFK2-Ctrl adipocytes 
(Fig. 38, C and D). These effects did not occur in iPFK2-KD adipocytes in the absence 
of etomoxir (see above; Fig. 38, A–C). Additionally, upon supplementation of etomoxir, 
treatment with rosiglitazone increased the phosphorylation of Akt in iPFK2-KD 
adipocytes in the presence of palmitate (Fig. 38 E), which was also not observed in 
iPFK2-KD adipocytes incubated without etomoxir (see above; Fig. 38 E). Collectively, 
these data suggest that inhibition of excessive fatty acid oxidation restores the effects of 
PPARγ activation on both suppression of adipocyte inflammatory response and 
stimulation of adipocyte insulin signaling in iPFK2-KD adipocytes. 
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Figure  38. Inhibition of fatty acid oxidation restores the effects of PPARγ 
activation on both suppression of adipocyte inflammatory response and stimulation 
of adipocyte insulin signaling. After differentiation for 6–8 days, stable iPFK2-KD and 
iPFK2-Ctrl adipocytes were treated with rosiglitazone (Rosi; 1 μM) or vehicle (0.1% 
DMSO) for 48 h. In the last 24 h, the cells were incubated with or without etomoxir 
(Eto; 100 μM) in the presence or absence of palmitate (Pal; 250 μM) for 24 h. 
Thereafter, the treated cells were subjected to the assays described under “Experimental 
Procedures.” For A and B, the production of ROS was measured using the nitro blue 
tetrazolium assay. Data are means ± S.E. (error bars), n = 4. A, ††, p < 0.01, iPFK2-KD 
vs. iPFK2-Ctrl under the same condition. ‡, p < 0.05, iPFK2-KD in the presence of 
palmitate vs. iPFK2-KD in the absence of palmitate under treatment with rosiglitazone. 
B, ††, p < 0.01 iPFK2-KD vs. iPFK2-Ctrl in the absence of etomoxir; ‡‡, p < 0.01 
iPFK2-KD in the presence of etomoxir vs. iPFK2-KD in the absence of etomoxir. C, 
changes in adipocyte inflammatory signaling. D, changes in adipocyte expression of 
proinflammatory cytokines. Data are means ± S.E. (error bars), n = 4. †, p < 0.05; ††, p 
< 0.01, iPFK2-KD/etomoxir/DMSO vs. iPFK2-KD/vehicle (Vehi)/DMSO for the same 
gene. ‡‡, p < 0.01, iPFK2-KD/etomoxir/rosiglitazone vs. iPFK2-KD/Vehi/DMSO; *, p < 
0.05, iPFK2-KD/etomoxir/rosiglitazone vs. iPFK2-KD/etomoxir/DMSO. E, changes in 
adipocyte insulin signaling. Before harvest, the cells were incubated with or without 
insulin (100 nM) for 30 min. 
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DISCUSSION 
 
            PFKFB3/iPFK2 has been identified as a target gene of PPARγ since the finding 
that troglitazone, an early TZD, increases PFKFB3/iPFK2 expression in adipocytes [110, 
156]. Two lines of evidence were obtained to further demonstrate the role of PPARγ in 
controlling PFKFB3/iPFK2 expression. Notably, disruption of PPARγ2 decreased 
PFKFB3/iPFK2 expression, whereas PPARγ2 overexpression rescued this defect. In 
addition, agonist(s) for PPARγ but not PPARγ and/or PPARγ stimulated the expression 
of adipocyte PFKFB3/iPFK2, which was attributed to transcription activation of the 
promoter of PFKFB3. Interestingly, the metabolic phenotype of PFKFB3/iPFK2-
disrupted mice was similar to that of PPARγ2-disrupted mice [120] and adipose tissue-
specific PPARγ-knock-out mice on an HFD [90]. This leads to the hypothesis that 
PFKFB3/iPFK2 is critically involved in the antidiabetic effect of PPARγ activation. To 
test this hypothesis, using PFKFB3/iPFK2-disrupted mice and PFKFB3/iPFK2- and 
PEPCK to rosiglitazone in PFKFB3+/– mice was not sufficient to compensate for the 
PFKFB3/iPFK2 disruption-associated decrease in the ability of adipose tissue to store 
fat. A possible explanation directly linked to the biochemical properties of these 
enzymes is that PFKFB3/iPFK2 generates both acetyl-CoA and glycerol 3-phosphate as 
the required substrates for lipogenesis and triglyceride synthesis in adipocytes, whereas 
GyK and PEPCK appear to only generate glycerol 3-phosphate via direct 
phosphorylation of glycerol [100] and through glyceroneogenesis [94], respectively. 
Also, it is possible that the stimulatory effects of GyK and PEPCK on adipocyte/adipose 
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tissue fat storage were offset by the PFKFB3/iPFK2 disruption-associated increase in 
adipose tissue fatty acid oxidation; given that PFKFB3/iPFK2 has an indirect effect on 
suppression of adipocyte fatty acid oxidation. Based on the current data, the possibility 
that PFKFB3/iPFK2 disruption generated an environment that could not allow GyK 
and/or PEPCK to stimulate fat storage cannot be ruled out and will be investigated by 
future study. 
            The contribution of PFKFB3/iPFK2 to the anti-diabetic effect of PPARγ 
activation is also attributable to the suppressive effect of PFKFB3/iPFK2 on adipocyte 
inflammatory response. Treatment with rosiglitazone brought about a decrease in HFD-
stimulated adipose mRNA levels of TNFα and IL-6 in wild-type mice but not in 
PFKFB3+/– mice. Further, a direct role for PFKFB3/iPFK2 in mediating the anti-
inflammatory effect of PPARγ activation was confirmed in a cell culture system. In 
PFKFB3/iPFK2-knockdown 3T3-L1 adipocytes, rosiglitazone did not decrease 
palmitate-induced mRNA levels of TNFα and IL-6 as it did in control adipocytes. This 
PFKFB3/iPFK2 knockdown-associated defect resulted in an inefficiency of rosiglitazone 
to decrease adipose resistinmRNAlevels and to increase adiponectin mRNA levels in 
both PFKFB3+/– mice and PFKFB3/iPFK2-knockdown adipocytes, which indicated 
adipose tissue/adipocyte dysfunction [158-160] and contributed to the lack of anti-
diabetic effect in rosiglitazone-treated PFKFB3+/– mice. 
            In conclusion, these data support the involvement of PFKFB3/iPFK2 in the anti-
diabetic effect of PPARγ activation. This role of PFKFB3/iPFK2 is evidenced by the 
fact that the intact PFKFB3/iPFK2 allows rosiglitazone to increase fat storage in the 
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adipocytes/adipose tissue and to suppress adipocyte/adipose tissue inflammatory 
response. These results indicate that selective activation of adipocyte PFKFB3/iPFK2 
may be a viable approach to generating the beneficial effects of PPARγ activation in the 
treatment of type 2 diabetes. 
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CHAPTER V  
THE ROLE OF PFKFB3/iPFK2 IN OVERNUTRITION-RELATED INTESTINE 
INFLAMMATION* 
 
INTRODUCTION 
 
            Overnutrition contributes to systemic insulin resistance that increases the risk of 
metabolic disorders. There are many studies focusing on metabolic disorders in liver, 
adipose tissue and skeletal muscle. However, little studies investigate the role of the 
intestine in overnutrition-related metabolic disorders. The intestine is the organ for 
digestion, absorption and assimilation. Nutritional signals after food ingestion stimulate 
intestinal enterocytes to secrete hormones and cytokines. Liver, adipose tissue and 
skeletal muscle adjust their function to maintain systemic homeostasis when respond to 
those hormones and cytokines secreted by the intestine [64]. For example, incretin 
hormones facilitate glucose uptake by muscle and suppress the production of glucose in 
liver [62, 63]. The hormones secreted by the intestine can control not only the intestinal 
motility and satiety but also the glucose homeostasis [64]. In HFD-induced obesity and 
insulin resistance mouse models, many genes related to lipid metabolism are changed in 
___________   
* Reprinted with permission from Guo, X., Li, H., Thomas, L.N., Sturino, J.M., and Wu, 
C. Disruption of PFKFB3/iPFK2 blunts the suppressive effect of rosiglitazone on diet-
induced intestine inflammatory response. J Nutr Biochem, 2012. [Epub ahead of print] 
Copyright 2012 by Elsevier B.V. 
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 the small intestine. Those fat-modulated genes are associated with insulin resistance 
[65]. In addition to digestion, absorption and assimilation, the intestine is also an organ  
for collection of microbes. There is a balance between the intestine and the intestinal 
microbiota. Failure to maintain the balance causes impairment of intestinal homeostasis, 
even systemic homeostasis [70]. Under overnutrition, gut microbiota are changed and 
promote the secretion of proinflammatory cytokines that are associated with the 
development and progression of insulin resistance and metabolic disorder [66, 71]. 
Mechanisms for the control of inflammation by microbiota could be due to that 
microbiota increase intestinal permeability [72, 73]. Therefore, the role of intestine in 
critically in regulating systemic homeostasis should be taken seriously. 
            Rosiglitazone is one of the thiazolidinediones (TZDs) that activate the nuclear 
receptor called Peroxisome Proliferator-activated receptor γ (PPARγ). Activation of 
PPARγ effectively improves systemic insulin sensitivity and lowers plasma glucose 
levels in both human patients and rodent models of type 2 diabetes [76-82]. PPARγ is at 
high abundance in adipose tissue and associated with adipocyte differentiation [89, 161]. 
As such, adipose tissue is considered to be the primary organ for the anti-diabetic effect 
of PPARγ activation. There are two mechanisms to explain the anti-diabetic effect of 
PPARγ activation [45, 81]. First, PPARγ activation by TZDs increases the capacity of fat 
storage in adipose tissue to reduce the circulating levels of free fatty acids [94-96, 100]. 
Second, PPARγ activation suppresses the adipose tissue inflammatory response [58, 97] 
and regulates adipokine expression [98, 101]. In the past decade, the anti-inflammatory 
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effect of PPARγ activation in intestine has been reported. Additionally, activation of 
PPARγ is shown to be effective for decreasing the inflammation in certain intestinal 
diseases [162-164]. Considering this, there is a need to define a role for intestine in anti-
diabetic effect of PPARγ activation. 
            PFKFB3 is the gene that encodes for the inducible 6-phosphofructo-2-kinase 
(iPFK2) that is highly expressed in adipose tissue [110]. PFKFB3/iPFK2 generates 
fructose-2,6-bisphosphate (F26P2), which is a powerful activator of 6-phosphofructo-1-
kinase (6PFK1) to enhance glycolysis [111, 112]. This effect is involved in adipocyte 
lipogenesis and triglyceride synthesis [110]. It has previous been shown that 
PFKFB3/iPFK2 regulates diet-induced adiposity and systemic insulin resistance. For 
example, on an HFD, PFKFB3+/– mice had a smaller increase in adiposity than wild type 
littermates. Compared with wild type littermates, however, PFKFB3+/– mice exhibited 
increased severity of HFD-induced adipose tissue dysfunction, decreased insulin 
signaling, and increased inflammatory response. Therefore, PFKFB/iPFK2 protects 
against diet-induced insulin resistance and adipose tissue inflammatory response, 
although contributing to adiposity. However, it is unknown whether the protection of 
PFKFB3/iPFK2 influences the inflammatory response in other organs or tissues such as 
the intestine. The present study provides evidence to support a role of adipose 
PFKFB3/iPFK2 in regulating diet-induced intestinal inflammatory response. 
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MATERIALS AND METHODS 
 
Animal Experiments  
            All mice were maintained on a 12:12-h light-dark cycle (lights on at 06:00). For 
PFKFB3/iPFK2 distribution study, male wild-type C57BL6/J mice were fed ad libitum. 
At 12 – 14 weeks of age, mice were euthanized to collect tissue samples. In order to 
investigate the effect of diet on intestine, male wild-type C57BL/6J mice were fed with a 
high fat diet (HFD) (60% fat calories, 20% protein calories, and 20 carbohydrate 
calories) or a low fat diet (LFD) (10% fat calories, 20% protein calories, and 70 
carbohydrate calories) for 12 weeks at the age of 5 – 6 weeks. Both diets are products of 
Research Diets, Inc (New Brunswick, NJ) and contain the same of amount of casein, L-
cystein, cellulose, soybean oil, and minerals. However, the HFD contains much more 
lard and maltodextrin but much less sucrose and none corn starch compared to the LFD. 
At 12 – 14 weeks of age, mice were euthanized to collect tissue samples. In order to 
investigate the function of PFKFB3/iPFK2 in intestine, PFKFB3/iPFK2 disrupted mice 
were introduced. Homozygous disruption of PFKFB3/iPFK2 is embryonic lethal [133]. 
Thus, PFKFB3+/– mice used in the present study. Considering that rosiglitazone lowers 
the levels of plasma glucose and improves insulin sensitivity only in diabetic mice, male 
PFKFB3+/– and wild-type littermates (C57BL/6J background) were fed an HFD prior to 
treatment with rosiglitazone. It has been recently shown that feeding an HFD to 
PFKFB3+/– mice exacerbates systemic insulin resistance and adipose tissue inflammatory 
response [165]. At the age of 5 - 6 weeks, mice were fed an HFD or an LFD for 12 
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weeks. During the last 4 weeks of the feeding regimen, HFD-fed mice were treated with 
rosiglitazone (10 mg/kg/day in PBS; Avandia tablets) or vehicle (PBS) via oral gavages. 
LFD-fed age-matched male mice were served as control and received no treatment. At 
the end of the feeding or treatment regimen, all mice were fasted for 4 h before sacrifice 
for collection of blood and tissue samples [135-137]. After anesthesia with 
ketamine/Xylene (100 mg/kg / 10 mg/kg body weight) via intraperitoneal injection, the 
abdomen was quickly opened. The intestine samples were frozen in liquid nitrogen and 
then stored at -80 °C for further study. All intestine samples were got rid of the digesta 
or feces. All study protocols were reviewed and approved by the Institutional Animal 
Care and Use Committee of Texas A&M University. 
 
Determination of PFKFB3 mRNA and iPFK2 Amount  
            PFKFB3 mRNA and iPFK2 amount in the intestine were determined using real-
time RT-PCR and Western blot, respectively, as described below. 
 
RNA Isolation, Reverse Transcription, and Real-time PCR  
            The total RNA was isolated from frozen intestine (jejunum and ileum) samples. 
RNA isolation and real-time RT-PCR were conducted as previously described [137]. 
The mRNA levels were analyzed for TLR4, TNFα, and IL-6. 
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Western Blots  
            Lysates were prepared from intestine (jejunum and ileum) samples. Western 
blots were conducted as previously described [136, 137]. The levels of iPFK2, JNK, 
phospho-JNK, NF-κB p65 and phospho-p65 were analyzed. 
 
Measurement of Microbiota Composition  
            Before and during treatment with rosiglitazone or PBS, fecal samples of HFD-
fed mice were collected, pooled and homogenized. Total genomic DNA was isolated and 
subjected to real-time PCR using primers specific to bifidobacteria [166] and lactobacilli 
[167]. 
 
Evaluation of Systemic Insulin Sensitivity  
            Plasma levels of glucose and insulin were measured as previously described and 
used to calculate homeostasis model assessment of insulin resistance (HOMA-IR), an 
indicator of systemic insulin resistance, using the following equation: HOMA-IR = basal 
glucose (mmol/L)×basal insulin (mU/L)/22.5. 
 
Statistical Methods  
            Numeric data are presented as means ± SE (standard error). Statistical 
significance was assessed by unpaired, two-tailed ANOVA or Student’s t test. 
Differences were considered significant at the two-tailed P < 0.05.  
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RESULTS 
 
PFKFB3/iPFK2 is Expressed Abundantly in the Intestine  
            The expression profile of PFKFB3/iPFK2 was determined in various tissues in 
wild-type mice. Among the key tissues that are involved in the regulation of systemic 
insulin sensitivity and metabolic homeostasis, PFKFB3/iPFK2 is expressed at high 
levels in the intestine and white adipose tissue but expressed at very low levels in the 
liver, muscle, and brown adipose tissue (Fig. 39). PFKFB3/iPFK2-associated metabolic 
changes are due primarily to alteration of PFKFB3/iPFK2 in the white adipose tissue.  
 
 
 
Figure  39. PFKFB3/iPFK2 expression in key metabolic tissues. Male wild-type 
C57BL/6J mice were fed ad libitum. At 12–14 weeks of age, mice were euthanized for 
collection of tissue samples. Tissue lysates were prepared to determine the amount of 
iPFK2 using Western blot analyses. BAT, brown adipose tissue; Epi-WAT, epididymal 
white adipose tissue; PN, perinephric; Mes, mesenteric. 
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The role of PFKFB3/iPFK2 in white adipose tissue was described in previous study. 
These data suggest that except to the white adipose tissue, the intestine also plays a role 
in PFKFB3/iPFK2-associated metabolic changes. 
 
Diet Effects the Expression of PFKFB3/iPFK2 in the Intestine  
            To determine the role of diet in the expression of intestinal PFKFB3/iPFK2, the 
protein levels of intestinal PFKFB3/iPFK2 in LFD-fed and HFD-fed wild-type mice 
were measured. Compared to the LFD-fed wild-type mice, the levels of intestinal 
PFKFB3/iPFK2 were significantly higher in HFD-fed wild-type mice (Fig. 40). This 
data suggests that HFD feeding increases the expression of PFKFB3/iPFK2 in the 
intestine. This increase in intestine PFKFB3/iPFK2 expression appears to be a defensive 
response, given a critical role for PFKFB3/iPFK2 in protecting against diet-induced 
intestine inflammatory response. 
 
HFD Feeding Induces Intestine Inflammatory Response 
            Intestine inflammatory response was examined. Compared with controls, the 
phosphorylation of JNK1 in intestine of HFD-fed mice was increased (Fig. 41 A), 
although the phosphorylation of NF-κB was undetectable in mice on either an HFD or 
LFD (data not shown). Additionally, in HFD-fed mice, intestine mRNA levels of TNFα 
and IL-6 were significantly higher than their respective levels in controls (Fig. 41 B). 
These results demonstrate an increase in intestine inflammatory response in HFD-fed 
mice. 
 100 
 
 
 
 
Figure  40. Diet effects the expression of PFKFB3/iPFK2 in the intestine. Male wild-
type C57BL/6J mice, at 5–6 weeks of age, were fed an LFD or HFD for 12weeks. 
Intestine lysates were subjected to Western blot analyses to measure intestine amount of 
iPFK2. 
 
 
 
 
Figure  41. Effects of HFD feeding on intestine inflammatory responses. Male wild-
type C57BL/6J mice, at 5–6 weeks of age, were fed an LFD or HFD for 12 weeks. (A) 
Intestine lysates were subjected to Western blot analyses to measure intestine amount of 
JNK and phospho-JNK. (B) The total RNA of intestine was prepared to determine the 
expression of proinflammatory cytokines using real-time RT-PCR. Data are means ± 
S.E., n=4. *P < 0.05 HFD vs. LFD for the same gene. 
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PFKFB3/iPFK2 Disruption Blunts Dietary Response of Intestine iPFK2 
            The response of intestine PFKFB3/iPFK2 to HFD feeding was examined in 
PFKFB3+/− mice. Heterozygous PFKFB3 disruption was confirmed using PCR analyses 
of genomic DNA (Fig. 42 A). On an LFD, intestine iPFK2 amount in PFKFB3+/− mice 
was lower than in wild type littermates (C57BL/6J background) (Fig. 42 B), further 
demonstrating PFKFB3/iPFK2 disruption. Upon feeding an HFD, PFKFB3+/−mice did 
not exhibit an increase in intestine iPFK2 amount as did wild-type mice. Thus, intact 
PFKFB3/iPFK2 appears to be required for a defensive increase in intestine 
PFKFB3/iPFK2 in response to HFD feeding. 
 
 
 
Figure  42. Effects of PFKFB3/iPFK2 disruption on dietary response of intestine 
iPFK2. (A) Validation of heterozygous PFKFB3/iPFK2 disruption. Genomic DNA of 
PFKFB3+/− mice and wild-type littermates were subjected to PCR analyses using an 
exon 2-specific primer with an exon 3-specific primer (WT) or a neomycin-specific 
primer (Neo). (B) Male PFKFB3+/− mice and wild-type littermates, at 5–6 weeks of 
age, were fed an LFD or HFD for 12 weeks. Intestine lysates were prepared to determine 
the amount of iPFK2 using Western blot analyses. 
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PFKFB3/iPFK2 Disruption Exacerbates HFD-induced Intestine Inflammatory 
Response and Partially Blunts the Effects of PPARγ Activation 
            The effect of PFKFB3/iPFK2 disruption on diet-induced intestine inflammatory 
response was examined. Compared with HFD-fed wild type littermates, HFD-fed 
PFKFB3+/− mice exhibited an increase in the mRNA levels of intestine TLR4 (Fig. 43 
A), a receptor whose activation leads to increased proinflammatory responses. In 
addition, the phosphorylation of JNK1 and NF-κB p65, two key signaling pathways that 
mediate proinflammatory responses, in intestine of HFD-fed PFKFB3+/− mice was much 
greater than that in controls (Fig. 43 B). Consistent with increased signaling through 
proinflammatory pathways, the mRNA levels of intestine TNFαand IL-6 in HFD-fed 
PFKFB3+/− mice were higher than their respective levels in controls (Fig. 43 C). These 
results, in combination, suggest a protective role for PFKFB3/iPFK2 in diet-induced 
intestine inflammatory response.  
            PPARγ has a protective role in intestine inflammation[168]. The effect of PPARγ 
activation on diet-induced intestine inflammatory response was examined. Upon 
treatment with rosiglitazone, the mRNA levels of TLR4 (Fig. 43 A), the phosphorylation 
of JNK1 (Fig. 43 B), and the mRNA levels of TNFα and IL-6 (Fig. 43 C) were 
decreased in intestine of HFD-fed wild-type littermates and, to a much lesser degree, in 
intestine of HFD-fed PFKFB3+/− mice. Additionally, intestine NF-κB p65 
phosphorylation remained high in HFD-fed PFKFB3+/− mice compared with that in 
HFD-fed wild-type littermates after treatment with rosiglitazone (Fig. 43 B). Together, 
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these results suggest that PFKFB3/iPFK2 disruption partially blunts the effect of PPARγ 
activation on suppressing HFD-induced intestine inflammatory response. 
 
PFKFB3/iPFK2 Disruption Decreases Intestine Proliferation of Lactobacilli in 
HFD-fed Mice in Response to PBS and/or Rosiglitazone Treatment 
            Intestinal microbiotas not only control the inflammatory response in intestine but 
also critically regulate systemic insulin sensitivity [67-69]. The fecal samples of HFD-
fed mice were analyzed in order to determine changes in proliferation of beneficial 
intestinal bacteria, specifically those belonging to the genera Lactobacillus and 
Bifidobacterium. Compared with controls, the proliferation of Lactobacillus in HFD-fed 
PFKFB3+/− mice was decreased upon treatment with either rosiglitazone or PBS (Fig. 
44 A). However, bifidobacteria did not show significant differences among all four 
groups of mice (Fig. 44 B). These results suggest that oral dosing does not affect the 
proliferation of lactobacilli in wild-type animals, however oral dosing decreases their 
proliferation when PFKFB3/iPFK2 is disrupted. Furthermore, treatment with 
rosiglitazone has a limited role in altering intestine proliferation of Lactobacillus and 
Bifidobacterium in HFD-fed mice. 
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Figure  43. Involvement of PFKFB3/iPFK2 in the effect of PPARγ activation on 
diet-induced intestine inflammatory response. Male PFKFB3+/− mice and wild-type 
littermates, at 5–6 weeks of age, were fed an HFD for 12 weeks and treated with 
rosiglitazone (Rosi, 10 mg/kg/day in PBS) or vehicle (PBS) orally for the last 4 weeks of 
the feeding regimen. (A) Intestine mRNA levels of TLR4 were quantified using real-
time RT-PCR. (B) Intestine inflammatory signaling. Intestine lysates were prepared to 
determine the amount and phosphorylation states of JNK and NF-κB p65 using Western 
blot analyses. (C) Intestine mRNA levels of TNFα and IL-6 were quantified using real-
time RT-PCR. Left panel, representative PCR products; and right two panels, relative 
intestine mRNA levels. For panels (A) and (C), numeric data are means ± S.E.; n=4–6. 
*P < 0.05 and **P < 0.01, rosiglitazone vs. vehicle for the same genotype; † P < 0.05 
and ††P < 0.01, PFKFB3+/− vs. wild type for the same treatment (rosiglitazone or 
vehicle). 
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Figure  44. Alterations of intestine microbiota composition. Male PFKFB3+/− mice 
and wildtype littermates, at 5–6 weeks of age, were fed an HFD for 12 weeks and treated 
with rosiglitazone (Rosi, 10 mg/kg/day in PBS) or vehicle (PBS) orally for the last 4 
weeks of the feeding regimen. Before, during and after treatment with rosiglitazone or 
PBS, fecal samples of HFD-fed mice were collected, pooled and homogenized. Total 
genomic DNA was isolated and subjected to quantitative real-time PCR using primers 
specific to Lactobacillus (A) and Bifidobacterium (B). Ct, cycle threshold. 
 
 
 
PFKFB3/iPFK2 Disruption Blunts the Insulin-sensitizing Effect of PPARγ 
Activation 
            Feeding an HFD to mice induces intestine inflammatory response, which 
contributes to the development of systemic insulin resistance [169]. Upon treatment with 
rosiglitazone, HFD-fed wild-type mice displayed a marked decrease in HOMA-IR (Fig. 
45), an indicator of insulin resistance. Significantly, the decrease in HOMA-IR in HFD-
fed and rosiglitazone-treated wild-type mice was accompanied by decreased intestine 
inflammatory response as described above (Fig. 43). In contrast, treatment with 
rosiglitazone only caused an insignificant decrease in HOMA-IR in HFD-fed PFKFB3+/− 
mice (Fig. 45), which was accompanied by increased intestine inflammatory response. 
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The latter was at a much greater degree than that in HFD-fed and rosiglitazone-treated 
wild-type mice. These results, in combination, indicate a positive correlation between 
systemic insulin resistance and intestine inflammatory response, which is regulated by 
PFKFB3/iPFK2. 
 
DISCUSSION 
 
             In wild-type mice, feeding an HFD alters the fat-regulatory genes in the 
intestine, which contributes to systemic insulin resistance [65]. In PFKFB3+/– mice,  
 
 
Figure  45. PFKFB3/iPFK2 regulation of systemic insulin sensitivity. Male 
PFKFB3+/− mice and wild-type littermates, at 5–6 weeks of age, were fed an HFD for 12 
weeks and treated with rosiglitazone (Rosi, 10 mg/kg/day in PBS) or vehicle (PBS) 
orally for the last 4 weeks of the feeding regimen. At the end of feeding/treatment 
regimen, blood samples were collected and used to measure plasma levels of glucose 
and insulin. HOMA-IR was calculated using the following equation: HOMA-IR=basal 
glucose (mmol/L)×basal insulin (mU/L)/22.5. Data are means ± S.E.; n=4–6. **P < 
0.01, rosiglitazone vs. vehicle for the same genotype; † P < 0.05 and ††P < 0.01, 
PFKFB3+/− vs. wild type for the same treatment (rosiglitazone or vehicle). 
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feeding an HFD caused a much greater increase in the severity of HFD-induced intestine 
inflammatory response and systemic insulin resistance. PFKFB3/iPFK2 has been 
identified as a target gene of PPARγ because activation of PPARγ increases 
PFKFB3/iPFK2 expression in adipocyte [110, 156]. In addition to adipose tissue, the 
intestine is another organ that abundantly expresses PFKFB3/iPFK2. Therefore, 
activation of PPARγ may pay a role in intestinal PFKFB3/iPFK2 expression. Also, 
PFKFB3/iPFK2 may be involved in the anti-diabetic effect of PPARγ activation. In the 
present study, PFKFB3/iPFK2-disrupted mice were using to determine the extent to 
which PFKFB3/iPFK2 accounts for the anti-diabetic effect of PPARγ activation. 
Treatment with rosiglitazone brought about a decrease in HFD-induced intestinal mRNA 
levels of TLR 4, TNFα and IL-6, and the phosphorylation of JNK1 in wild-type mice, 
but a partial decrease in inflammatory markers in PFKFB3+/– mice. Additionally, the 
phosphorylation of intestinal JNK1 remained high in PFKFB3+/– mice compared with 
that in wild-type littermates after treatment with rosiglitazone. Together, these data 
indicate that PFKFB3/iPFK2 plays an important role in regulating HFD-induced 
intestinal inflammatory response and systemic insulin resistance.  
            In summary, activation of intestinal PFKFB3/iPFK2 may be an approach to 
reversing overnutrition related intestinal inflammation and systemic insulin resistance, 
thereby generating the beneficial effects for the treatment of type 2 diabetes. 
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CHAPTER VI 
 
SUMMARY AND CONCLUSIONS 
 
SUMMARY 
 
In wild-type mice, adiposity induced by overnutrition is a key contributor of 
systemic insulin resistance. However, in PFKFB3+/– mice, although bringing about a 
much smaller increase in adiposity, feeding an HFD caused a much greater increase in 
the severity of HFD-induced adipose tissue dysfunction and systemic insulin resistance 
than in wild-type littermates. These changes were attributed to the increased adipose 
tissue inflammatory response, which was evidenced by higher levels of proinflammatory 
cytokines in both isolated adipose tissue macrophages and adipocytes in PFKFB3+/– 
mice. Consistently, in cultured adipocytes, knockdown of PFKFB3/iPFK2 caused a 
decrease in lipid accumulation and an increase in the status of oxidative stress, which 
were accompanied by enhanced inflammatory signaling, increased mRNA levels of 
TNFα and IL-6, and decreased insulin signaling. PFKFB3/iPFK2 plays a novel and 
unique role in regulating HFD-induced adipose tissue dysfunction and systemic insulin 
resistance in a manner independent of adiposity.    
The unique role of PFKFB3/iPFK2 in dissociating HFD-induced adiposity and 
adipose tissue dysfunction is attributed, at a large extent, to the metabolic properties of 
PFKFB3/iPFK2. Notably, PFKFB3/iPFK2 stimulates adipocyte glycolysis [110]. An 
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increase in PFKFB3/iPFK2-stimulated glycolysis not only provides lactate and pyruvate 
(which are converted into acetyl-CoA and used for lipogenesis to provide free fatty 
acids), but also increases the production of dihydroxyacetone phosphate, which is 
converted into glycerol-3-phosphate as a required substrate for adipocyte triglyceride 
synthesis. Upon disruption of PFKFB3/iPFK2, both glycolysis and glycolysis-derived 
lipogenesis and triglyceride synthesis are impaired, which is supported by the data that 
PFKFB3/iPFK2-knockdown adipocytes exhibited a decrease in the incorporation of 
glucose into lipid, and thereby adipocyte lipid accumulation. This contributes to a 
smaller gain in adiposity in PFKFB3+/– mice after HFD feeding. Importantly, the 
impairment in using glucose as a fuel due to disruption of PFKFB3/iPFK2 likely causes 
a compensatory increase in fatty acid oxidation, which is supported by increased 
expression of CPT1, as well as PPARγ and PGC1 in adipose tissue of PFKFB3+/– mice. 
The compensatory increase in fatty acid oxidation not only contributes to a smaller gain 
in adiposity in PFKFB3+/– mice after HFD feeding, but more importantly, appears to 
trigger oxidative stress. In support of this concept, PFKFB3/iPFK2-knockdown 
adipocytes exhibited an increase in the production of ROS under both basal and 
palmitate-stimulated conditions. Furthermore, inhibition of fatty acid oxidation by 
etomoxir caused a marked decrease in palmitate-stimulated production of ROS in 
PFKFB3/iPFK2-knockdown adipocytes. In agreement with the role oxidative stress in 
disturbing adipokine expression and initiating the inflammatory response in adipocytes 
[45], the increased production of ROS in PFKFB3/iPFK2-knockdown adipocytes was 
associated, on the one hand, with inappropriately altered expression of resistin and 
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adiponectin, and on the other hand, with increased phosphorylation states of JNK and 
NFκB p65 and increased mRNA levels of TNFα and IL-6 in PFKFB3/iPFK2-
knockdown adipocytes. Apparently, PFKFB3/iPFK2 links nutrient metabolism and 
adipocyte function.  
The role of adipose tissue dysfunction in causing systemic insulin resistance has 
been well documented [125, 126]. Indeed, this role is illustrated by at least two plausible 
mechanisms [45-48]. In the first mechanism, adipose tissue dysfunction causes an 
increase in the production of free fatty acids, resistin, and retinol binding protein 4 
(RBP4) and a decrease in the production of adiponectin. These factors are carried to the 
insulin-sensitive tissues including the liver and skeletal muscle through circulation to 
impair insulin signaling and ultimately bring about systemic insulin resistance [130-132, 
170]. In the second mechanism, adipose tissue-derived proinflammatory cytokines are 
similarly carried to insulin-sensitive tissues through circulation to directly impair insulin 
signaling in the tissues [128, 171, 172]. In the present study, PFKFB3+/– mice exhibited 
an increase in the severity of HFD-induced systemic insulin resistance and glucose 
intolerance. This was attributed, at least in part, to increased adipose tissue dysfunction, 
as evidenced by increased adipose tissue lipolysis, inappropriate adipokine expression, 
and decreased insulin signaling, as well as increased expression of proinflammatory 
cytokines including TNFα and IL-6 in the adipose tissue. These data support a pivotal 
role for PFKFB3/iPFK2 in protecting against HFD-induced adipose tissue dysfunction, 
and thereby systemic insulin resistance. Moreover, because PFKFB3/iPFK2 disruption-
associated changes in adipose tissue dysfunction were nearly identical to those in 
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PFKFB3/iPFK2-knockdown adipocytes, PFKFB3/iPFK2 in adipocytes is thereby 
responsible largely for the regulation of adipose tissue function. It should be pointed out 
that PFKFB3/iPFK2 is also expressed in tissues other than adipose tissue [133]. Thus, a 
possible role for PFKFB3/iPFK2 in non-adipose tissue in regulating systemic insulin 
sensitivity cannot be ruled out.    
It is also a novel finding that disruption of PFKFB3/iPFK2 exacerbated HFD-
induced adipose tissue inflammatory response, which was also independent of adiposity. 
Additionally, the increased adipose tissue inflammatory response was independent of 
macrophage accumulation in adipose tissue. In a generally accepted concept, HFD-
induced adipose tissue inflammatory is characterized by increased production of 
proinflammatory cytokines, which is positively correlated with macrophage infiltration 
[125, 126]. However, several lines of new evidence suggest that the inflammatory status 
of macrophages is more important than the number of macrophages in terms of 
controlling the production of proinflammatory cytokines in the adipose tissue. For 
example, mice that lack PPARγ in macrophages exhibit fewer macrophages in adipose 
tissue but have higher mRNA levels of IL-6 than wild-type control mice [173]. In 
contrast, treatment with rosiglitazone, a PPARγ agonist, increases the abundance of 
macrophages in adipose tissue, but decreases the production of proinflammatory 
cytokines such as IL-18 [97]. Considering this, disruption of PFKFB3/iPFK2 appears to 
increase the inflammatory activity of the infiltrated macrophages. This notion is indeed 
supported by the data that the mRNA levels of TNFα and IL-6 were higher in 
macrophages isolated from PFKFB3+/– mice than in wild-type littermates. Therefore, 
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disruption of PFKFB3/iPFK2 exacerbates HFD-induced adipose tissue inflammatory 
response in a manner depending on increasing macrophage inflammatory status rather 
than macrophage infiltration. However, further study is required to elucidate the 
underlying mechanisms by which disruption of PFKFB3/iPFK2 blunts HFD-induced 
macrophage infiltration into adipose tissue. In gain-of-function study, adipocyte-specific 
PFKFB3 over-expression increased adiposity but suppressed overnutrition induced 
adipose tissue inflammatory response and improved insulin sensitivity.  
            PFKFB3/iPFK2 has been identified as a target gene of PPARγ since the finding 
that troglitazone, an early TZD, increases PFKFB3/iPFK2 expression in adipocytes [110, 
156]. At the integrative level, the metabolic phenotype of PFKFB3/iPFK2-disrupted 
mice was similar to that of PPARγ2-disrupted mice [120] and adipose tissue-specific 
PPARγ-knock-out mice on an HFD [90]. This leads to the hypothesis that 
PFKFB3/iPFK2 is critically involved in the antidiabetic effect of PPARγ activation. 
Upon treatment of PFKFB3+/– mice with rosigalitazone, PFKFB3/iPFK2 appears to be 
needed for PPARγ activation to fully suppress diet-induced intestine inflammatory 
response. Thus, iPFK2 is needed for the anti-diabetic effect PPARγ activation. 
            The contribution of PFKFB3/iPFK2 to the anti-diabetic effect of PPARγ 
activation is also attributable to the suppressive effect of PFKFB3/iPFK2 on adipocyte 
inflammatory response. Treatment with rosiglitazone brought about a decrease in HFD-
stimulated adipose mRNA levels of TNFα and IL-6 in wild-type mice but not in 
PFKFB3+/– mice. Further, a direct role for PFKFB3/iPFK2 in mediating the anti-
inflammatory effect of PPARγ activation was confirmed in a cell culture system. In 
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PFKFB3/iPFK2-knockdown 3T3-L1 adipocytes, rosiglitazone did not decrease 
palmitate-induced mRNA levels of TNFα and IL-6 as it did in control adipocytes. This 
PFKFB3/iPFK2 knockdown-associated defect resulted in an inefficiency of rosiglitazone 
to decrease adipose resistin mRNA levels and to increase adiponectin mRNA levels in 
both PFKFB3+/– mice and PFKFB3/iPFK2-knockdown adipocytes, which indicated 
adipose tissue/adipocyte dysfunction [158-160] and contributed to the lack of anti-
diabetic effect in rosiglitazone-treated PFKFB3+/– mice. 
            In the adipose tissue, both macrophages and adipocytes are key determinants of 
overnutrition-induced adipose tissue inflammatory response[126, 174]. Attention has 
been increasingly paid to the effect of PPARγ activation on suppression of the 
proinflammatory function of macrophages [175, 176]. Treatment with rosiglitazone 
effectively reduced the phosphorylation of JNK1 and NF-κB p65 in control adipocytes 
but not in PFKFB3/iPFK2-knockdown adipocytes. This is consistent with the 
observation that rosiglitazone blunted palmitate-induced ROS production in control 
adipocytes but not in PFKFB3/iPFK2-knockdown adipocytes. When PFKFB3/iPFK2 
disruption-associated excessive fatty acid oxidation was brought down with etomoxir 
treatment, rosiglitazone was able to decrease inflammatory response and stimulate 
insulin signaling in PFKFB3/iPFK2-knockdown adipocytes. Clearly, PFKFB3/iPFK2 
contributes to the anti-inflammatory effect of PPARγ activation through a mechanism 
involving suppression of excessive fatty acid oxidation in adipocytes. 
             PFKFB3/iPFK2 disruption exacerbates diet-induced adipose tissue inflammatory 
response. At the cellular level, PFKFB3/iPFK2 disruption-associated increase in fatty 
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acid oxidation leads to increased production of ROS and oxidative stress, thereby 
triggering adipocyte inflammatory response. This mechanism may also exist in intestine, 
given that PFKFB3/iPFK2 is abundantly expressed in intestine. In the present study, 
intestine iPFK2 amount in PFKFB3/iPFK2-disrupted mice was lower than that in wild-
type mice and did not respond to HFD feeding as did intestine iPFK2 in wild-type mice 
in a defensive way. Furthermore, intestine iPFK2 amount negatively correlated with the 
degree of intestine inflammatory response. Because of this, it appears to be clear that 
intact PFKFB3/iPFK2 is required for full protection of overnutrition-induced intestine 
inflammatory responses. At this point, however, the extent to which the PFKFB3/iPFK2 
in intestine cells, in particular the PFKFB3/iPFK2 in intestinal epithelial cells, protects 
against diet-induced intestine inflammatory response is unknown. What should also be 
noted is that adipose tissue inflammatory response is elevated in PFKFB3/iPFK2-
disrupted mice.  Of importance, the status of adipose tissue inflammatory response 
determines the outcome of inflammatory responses in distal tissues including the liver. 
As such, a possible contribution of elevated adipose tissue inflammation to an increase in 
diet-induced intestine inflammatory response in PFKFB3/iPFK2-disrupted mice cannot 
be ruled out. Considering this, there may exist a vicious cycle for inflammatory 
responses between adipose tissue and intestine, regardless of how an initiator triggers 
inflammatory responses. 
            The essential role for PFKFB3/iPFK2 in protecting against diet induced intestine 
inflammatory response is further supported by the involvement of PFKFB3/iPFK2 in the 
anti-inflammatory effect of PPARγ activation. As a target gene of PPARγ, 
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PFKFB3/iPFK2 is stimulated by TZDs [110, 156]. Of significance, intact 
PFKFB3/iPFK2 is needed for actions of active PPARγ on channeling fatty acids to 
triglyceride synthesis to reduce excessive fatty acid oxidation associated production of 
ROS, thereby suppressing inflammatory signaling through the JNK1 and NF-κB 
pathways and decreasing proinflammatory cytokine expression in adipocytes/adipose 
tissue. In addition to causing an increase in major intestine proinflammatory indicators, 
PFKFB3/iPFK2 disruption also partially blunted the effect of rosiglitazone on 
suppressing diet-induced intestine inflammatory response. These changes in intestine 
inflammatory response were nearly identical to those observed in adipose tissue in 
PFKFB3/iPFK2-disrupted mice upon treatment with rosiglitazone. Because of this, it is 
conceivable that intact PFKFB3/iPFK2 is needed for PPARγ activation to suppress 
overnutrition-induced intestine inflammatory response. On the other hand, although 
PPARγ activation brought about an anti-inflammatory effect in intestine in a manner 
consistent with that reported previously[168], suppressing diet-induced adipose tissue 
inflammatory response may be a prerequisite for PPARγ activation to suppress diet-
induced intestine inflammatory response, given the primary role played by adipose tissue 
in the actions of PPARγ activation. Indeed, failure of rosiglitazone in fully suppressing 
diet-induced intestine inflammatory response reported herein was accompanied by 
defects in actions of rosiglitazone on reserving adipose tissue inflammatory response in 
PFKFB3/iPFK2-disrupted mice.  
            Suppressing inflammatory responses by active PPARγ underlies the insulin-
sensitizing and antidiabetic effects of TZDs. The degree of intestine inflammatory 
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response in rosiglitazone- and/or control-treated PFKFB3/iPFK2-disrupted mice and 
wild-type mice positively correlated with insulin resistance, indicated by HOMA-IR 
results. This observation argues in favor of the notion that PFKFB3/iPFK2 protection of 
diet-induced intestine inflammatory response is of importance to systemic insulin 
sensitivity and glucose homeostasis, as well as insulin sensitization brought about by 
PPARγ activation. As discussed before, there may exist a vicious cycle for inflammatory 
responses between adipose tissue and intestine during overnutrition. Considering this, 
intact PFKFB3/iPFK2 likely enables PPARγ activation to suppress inflammatory 
responses in both adipose tissue and intestine to achieve a systemic insulin sensitizing 
effect. In other words, intact PFKFB3/iPFK2 enables PPARγ activation to suppress 
intestine inflammatory response to contribute to systemic insulin sensitization by 
working with or without PPARγ suppression of adipose tissue inflammatory response in 
a manner involving PFKFB3/iPFK2. 
            In intestine, microbiota not only controls energy absorption but also critically 
regulates inflammatory responses of intestine cells [64, 66, 73]. New evidence further 
demonstrates that interactions between HFD and microbiota promote inflammation in 
small intestine, which precedes and correlates with obesity and insulin resistance. In the 
present study, HFD-fed PFKFB3/iPFK2-disrupted mice showed a decrease in the 
proliferation of intestinal lactobacilli in response to treatment of either rosiglitazone or 
PBS compared with HFD-fed wild-type mice. These results, on the one hand, suggest 
that PFKFB3/iPFK2 disruption creates an intestinal environment that allows oral dosing 
to alter the composition of sensitive microorganism. On the other hand, treatment with 
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rosiglitazone has a limited role in altering the proliferation of intestinal Lactobacillus. 
Although it is unknown whether or not decreased proliferation of Lactobacillus 
contributes to an increase in intestine inflammatory response in PFKFB3/iPFK2-
disrupted mice, a potential role for PFKFB3/iPFK2 in modulating the interactions 
between intestinal microorganism and intestine cells could serve as additional 
mechanism(s) by which PFKFB3/iPFK2 regulates intestine inflammatory response. This 
point is worthy of further investigation. 
 
  
CONCLUSIONS 
 
The present study demonstrates a novel and unique role for PFKFB3/iPFK2 in 
regulating adiposity and adipose tissue function, and thereby systemic insulin sensitivity. 
This role is manifested by the fact that disruption of PFKFB3/iPFK2 ameliorates HFD-
induced adiposity, but exacerbates HFD-induced adipose tissue dysfunction, in 
particular, adipose tissue inflammatory response, which contributes to an increase in the 
severity of systemic insulin resistance. In contrast, adipocyte-specific PFKFB3 over-
expression increased adiposity but suppressed overnutrition induced adipose tissue 
inflammatory response and improved insulin sensitivity. In addition, PFKFB3/iPFK2 
involves in the anti-diabetic effect of PPARγ activation. This role of PFKFB3/iPFK2 is 
evidenced by the fact that the intact PFKFB3/iPFK2 allows rosiglitazone to increase fat 
storage in the adipocytes/adipose tissue and to suppress adipocyte/adipose tissue 
inflammatory response. Mechanistically, the way by which PFKFB3/iPFK2 links two 
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adipose tissue-based mechanisms underlying the anti-diabetic effect of PPARγ activation 
is attributable to the effect of PFKFB3/iPFK2 on regulating adipocyte lipogenesis and 
triglyceride synthesis as well as adipocyte fatty acid oxidation-related ROS production 
and inflammatory response (Fig. 46). These results indicate that selective activation of 
adipocyte PFKFB3/iPFK2 may be a viable approach to generating the beneficial effects 
of PPARγ activation in the treatment of type 2 diabetes. 
            The mechanisms by which overnutrition induces intestine inflammation in 
relation to systemic insulin resistance and the actions of PPARγ activation remain to be 
elucidated. PFKFB3/iPFK2 plays a critical role in protecting against diet-induced 
intestine inflammatory response. Notably, major intestine inflammatory biomarkers, 
including the mRNA levels of TLR4, TNFαand IL-6, as well as the phosphorylation of 
JNK1 and NF-κB p65, in PFKFB3/iPFK2-disrupted mice were higher than their 
respective levels in wild-type controls under the condition of overnutrition, i.e., HFD 
feeding. Additionally, PFKFB3/iPFK2 appears to be needed for PPARγ activation to 
fully suppress diet-induced intestine inflammatory response. Considering this, activation 
of intestinal PFKFB3/iPFK2 may be an approach to reversing overnutrition-associated 
intestine inflammatory response and to improving systemic insulin sensitivity. 
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Figure  46. Involvement of PFKFB3/iPFK2 in the effects of PPARγ activation in 
adipocytes. Under the condition of overnutrition (A), adipocytes exhibit an increase in 
inflammatory response, which is brought about at least in part by excessive fatty acid 
oxidation. Upon activation of PPARγ (B), an increase in the expression of 
PFKFB3/iPFK2 enhances glycolysis to facilitate the synthesis of triglycerides (TG) via 
generating glycerol-3-phosphate and FFA (derived from acetyl-CoA following pyruvate 
oxidation). As a result, an increase in channeling FFA to triglyceride synthesis reduces 
fatty acid oxidation-associated production of ROS, thereby suppressing inflammatory 
signaling pathways through JNK1 and NF-κB and decreasing the expression of 
proinflammatory cytokines. DHAP, dihydroxyacetone phosphate; GLUT4, glucose 
transporter 4; FATP, fatty acid transport protein. 
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